

ORIGINAL ARTICLE

Open Access

Italian Society of Anesthesia, Analgesia, Resuscitation, and Intensive Care expert consensus statement on the use of lung ultrasound in critically ill patients with coronavirus disease 2019 (ITACO)



Luigi Vetrugno^{1,2*}, Francesco Mojoli³, Andrea Cortegiani^{4,5}, Elena Giovanna Bignami⁶, Mariachiara Ippolito^{4,5}, Daniele Orso², Francesco Corradi^{7,8}, Gianmaria Cammarota⁹, Silvia Mongodi³, Enrico Boero¹⁰, Carmine Iacovazzo¹¹, Maria Vargas¹¹, Daniele Poole¹², Daniele Guerino Biasucci¹³, Paolo Persona¹⁴, Tiziana Bove^{2,3}, Lorenzo Ball^{15,16}, Davide Chiumello¹⁷, Francesco Forfori⁷, Edoardo de Robertis⁹, Paolo Pelosi^{15,16}, Paolo Navalesi¹⁴, Antonino Giarratano^{4,5} and Flavia Petrini¹⁸

Abstract

Background: To produce statements based on the available evidence and an expert consensus (as members of the Lung Ultrasound Working Group of the Italian Society of Analgesia, Anesthesia, Resuscitation, and Intensive Care, SIAARTI) on the use of lung ultrasound for the management of patients with COVID-19 admitted to the intensive care unit.

Methods: A modified Delphi method was applied by a panel of anesthesiologists and intensive care physicians expert in the use of lung ultrasound in COVID-19 intensive critically ill patients to reach a consensus on ten clinical questions concerning the role of lung ultrasound in the following: COVID-19 diagnosis and monitoring (with and without invasive mechanical ventilation), positive end expiratory pressure titration, the use of prone position, the early diagnosis of pneumothorax- or ventilator-associated pneumonia, the process of weaning from invasive mechanical ventilation, and the need for radiologic chest imaging.

Results: A total of 20 statements were produced by the panel. Agreement was reached on 18 out of 20 statements (scoring 7–9; "appropriate") in the first round of voting, while 2 statements required a second round for agreement to be reached. At the end of the two Delphi rounds, the median score for the 20 statements was 8.5 [IQR 8.9], and the agreement percentage was 100%.

²University-Hospital of Friuli Centrale, ASU FC, Udine, Italy Full list of author information is available at the end of the article



^{*} Correspondence: luigi.vetrugno@uniud.it

¹Department of Medicine, University of Udine, Via Colugna n 50, 33100

Conclusion: The Lung Ultrasound Working Group of the Italian Society of Analgesia, Anesthesia, Resuscitation, and Intensive Care produced 20 consensus statements on the use of lung ultrasound in COVID-19 patients admitted to the ICU. This expert consensus strongly suggests integrating lung ultrasound findings in the clinical management of critically ill COVID-19 patients.

Keywords: Consensus, Coronavirus disease 2019, Intensive care, Lung ultrasound

Introduction

The use of lung ultrasound (LUS) in the intensive care setting has increased during the coronavirus disease 2019 (COVID-19) pandemic. It is being employed as a diagnostic and monitoring tool in patients with COVID-19related pneumonia—a condition which in some cases evolves into acute respiratory distress syndrome (ARDS) [1]. Lung ultrasound presents many advantages over other imaging techniques: it is readily available at the bedside, thus avoiding the need to transport patients to the radiology department, and it is radiation-free and highly repeatable, making it suitable for lung monitoring purposes [2]. Lung damage in COVID-19 pneumonia is mainly localized to the peripheral regions of the lungs, thus easily accessible to ultrasound [3]. The sensitivity and negative predictive value of LUS for COVID-19 pneumonia are both higher compared with those for chest X-ray [4]. Moreover, many studies show a close correlation between LUS and computed tomography (CT) scan findings [5]. Given the prolonged need for mechanical ventilation in COVID-19 and long intensive care unit (ICU) stay, repeated lung assessments are usually required. CT remains the reference imaging technique for lung assessment, but it is unsuitable as a monitoring tool due to its use of ionizing radiation. It also necessitates patient contact with healthcare providers outside the ICU, increasing the opportunity for this highly infectious disease to spread. The quantitative evaluation of lung disease by means of the LUS score provides a reliable method for assessing lung aeration in both ARDS and COVID-19, and may further help in monitoring lung recovery and in the daily optimization of ventilation strategies (i.e., positive endexpiration pressure [PEEP] titration, and the use of prone positioning) [6]. Finally, LUS permits the early bedside detection of complications, such as pneumothorax [7] and ventilator-associated pneumonia [8]. As a consequence, LUS has earned a leading position in the management of COVID-19 patients, being a reliable, time-sparing, and easy-to-learn alternative to traditional imaging techniques [9, 10]. However, the recent literature is mainly focused on its applications within the Emergency Department [11]. Although Canadian Internal Medicine Ultrasound (CIMUS) experts recently established their recommendations for medical inpatients with COVID-19 [12], consensus guidelines dedicated to COVID-19 ICU patients and officially acknowledged by a national intensive care

scientific society are lacking. To fill this gap, we aimed to produce an expert consensus on the bedside use of LUS in critically ill COVID-19 patients by a national panel of anesthesiology and intensive care physicians.

Methods

Consensus process design

This project was conducted according to a modified Delphi method to reach consensus on key aspects of the use of LUS in critically ill patients with COVID-19. Discussions were based on the available scientific evidence as well as the panel of experts' own clinical experience. The experts were selected by the project coordinators (LV and FM) based not only on their clinical and scientific interest in the topic [13] but also the opinion of intensivists who are not experts in LUS but who understand the context of critically ill COVID patients, and the potential role of lung ultrasound was invited. After an initial (online) kick-off meeting between the coordinators, the panelists, the methodologists (AC and DP), and the evidence review team (MI and DO), the project coordinators proposed a list of the most relevant clinical questions to the whole panel, which was then asked to submit a blind boolean vote ("agree/disagree on the relevance") as well as comments and proposals for their modification. In response, the coordinators made the appropriate changes to the clinical questions, which were finally approved by the whole panel through a second round of voting. The coordinators then assigned the work on each clinical question to a designated group of experts, each of which was led by a designated group head (PP, PN, EB, TB, and SM). The list of clinical guestions and the final consensus-based statements is shown in Table 1.

Systematic review of available evidence

A systematic review of MEDLINE, PubMed, EMBASE, and pre-print depositories (medRxiv and bioRxiv) was performed by the evidence review team with the added input of AC. The full search strategy can be found in Additional file 1. Inclusion and exclusion criteria and the PRISMA flow diagram (Fig. S1) of the inclusion/exclusion process can be found in Additional file 2 with the results of the first round of voting (Fig. S2). The full output of the search and the selection of potentially relevant articles (selected by MI and DO, according to the

Table 1 List of clinical questions and final consensus-based statements

10-clinical questions	20-consensus-based statements
A) Does LUS have a role to play in the diagnosis of COVID-19?	Statement 1: LUS should be integrated in the clinical workup to diagnose COVID-19 pneumonia. Statement 2: In patients with high clinical suspicion of COVID-19 and LUS findings compatible with ultrasonographic interstitial pneumonia, a negative nasal/oropharyngeal RT-PCR should not be used alone to exclude COVID-19. Statement 3: LUS should not be used alone to rule out SARS-CoV-2 pneumonia in suspected COVID-19.
B) Can LUS help in the early assessment of COVID-19 severity in the Emergency Department and/or at ICU admission?	Statement 4 : Sonographic multifocal and bilateral pleural and lung abnormalities, a high overall LUS score, and/or a high score in the gravity dependent areas can be used for the early assessment of COVID-19 severity in the Emergency Department and at ICU admission since all correlate with worsening patient outcomes – intended as the need for ICU admission, NIV, intubation, and a higher mortality rate.
C) Can LUS be used as a lung monitoring tool in COVID-19 patients undergoing non-invasive respiratory support (HFNC, CPAP, or NIV)?	Statement 5: In COVID-19 patients undergoing non-invasive respiratory support (HFNC, CPAP or NIV), LUS integrated with clinical and physiological parameters may contribute to predict non-invasive respiratory support outcome and early detect complications.
D) Can LUS be used as a lung monitoring tool in COVID-19 patients undergoing invasive mechanical ventilation?	Statement 6: LUS should be integrated into the multimodal assessment of disease progression and the response to treatments in mechanically ventilated COVID-19 patients. Statement 7: LUS should be integrated into the clinical decision-making process and monitoring of procedures, such as fibrobronchoscopy, in mechanically ventilated COVID-19 patients. Statement 8: LUS should be integrated into the clinical decision-making process and monitoring of treatments, such as antibiotics, in mechanically ventilated COVID-19 patients. Statement 9: LUS should be integrated into the clinical decision-making process and monitoring of fluid removal in mechanically ventilated COVID-19 patients.
E) Can LUS guide the titration of positive end expiratory pressure in severe COVID-19 patients receiving invasive mechanical ventilation?	Statement 10: LUS should be considered as an additional tool for PEEP titration in COVID-19.
F) Can LUS guide the use of prone positioning in patients with severe COVID-19?	Statement 11: LUS should be integrated into the assessment of patients considered potential responders to prone positioning, according to the focal and non-focal pattern of lung aeration loss. Statement 12: LUS can be used to monitor variations in lung aeration during prone positioning.
G) Can LUS help early diagnosis of pneumothorax in severe COVID-19 patients undergoing invasive mechanical ventilation?	Statement 13: LUS should be used in COVID-19 patients, in line with its clinical appropriateness as ascertained by studies in non-COVID-19 patients.
H) Can LUS help the early diagnosis of ventilator-associated pneumonia in severe COVID-19 patients undergoing invasive mechanical ventilation?	Statement 14: LUS should be used in COVID-19 patients, in line with its clinical appropriateness as ascertained by studies in non-COVID-19 patients.
I) Can LUS help the process of weaning severe COVID-19 patients from invasive mechanical ventilation?	Statement 15: We are unable to create any statement on the use of LUS in the assessment of patient readiness to sustain a spontaneous breathing trial (SBT). No study has evaluated the potential of LUS for this purpose in COVID-19 patients, and data in non-COVID-19 patients are conflicting. Statement 16: In association with standard clinical and physiological indexes, LUS can improve the prediction of SBT outcome in COVID-19 patients. Statement 17: In association with standard clinical and physiological indexes, LUS can improve the prediction of extubation failure in COVID-19 patients.
L) Can LUS decrease the need for radiologic chest imaging in severe COVID-19 patients?	Statement 18: In patients with known COVID-19 and severe symptoms, LUS should be performed instead of radiologic chest imaging as the first-line imaging test to monitor disease progression. Statement 19: LUS findings suggestive of pneumonia can render additional imaging techniques unnecessary, especially when the likelihood of an alternative diagnosis is low. Statement 20: In COVID-19 patients with severe symptoms, a negative LUS exam should prompt an additional radiologic chest imaging work-up.

PICO questions and criteria described in Table S1, Additional file 2) can be found in Additional file 3. The last literature search was completed on 16 January 2021. Other sources (i.e., reference lists from relevant articles [i.e., the snowballing method] and online journal issues) were surveyed after the last literature search and up until the end of the first round of voting so that any further relevant articles could be identified and included. The output of the search together with the full texts of all relevant articles was then sent to all panelists. Following the evaluation of the evidence, each panelist produced their statement and rationale in response to each of the given questions.

The Delphi rounds, consensus meeting

Two rounds of voting were held between March and June 2021. The respondents were blinded to each other's responses. In the first round, expert panelists responded to the online questionnaire and were offered the possibility of adding their opinions using an open text box. The research assistance team (CC, see the "Acknowledgements" section), with the input of the methodologist (AC), assessed and presented the results from round 1 in the form of bar graphs to facilitate the comments and clarifications offered by each participant during an online meeting. During this meeting, the panel openly discussed the statements/rationales on which agreement had not been reached. In some circumstances the discussion led the panelists to reconsider their initial opinions, whereas in others it resulted in the working group modifying the statements. A second round of blind online voting was then held. The results of the consensus process were tabulated and presented both descriptively and graphically. The process was closed on 16 June 2021.

Questionnaire and consensus criteria

The group's opinion on each statement and rationale was studied in terms of the score and the level of consensus reached by the panelists. The same criteria were applied to each of the statements and rationales. Opinions were expressed using a unique nine-point ordinal Likert-type scale, according to the model developed by UCLA-RAND Corporation (minimum score, 1 = full disagreement; maximum score, 9 = full agreement) [13]. This scale was split into three sections, indicating the level of agreement/disagreement: a score of 1-3 implicated rejection or disagreement ("not appropriate"); 4-6 implicated ("uncertainty"); and 7-9 implicated agreement/support ("appropriate"). Consensus was reached when (i) 75% or more of the respondents, i.e., at least 14 out of 18 experts (excluding the methodologists and the evidence review team), assigned a score within the 3point ranges 1-3 or 7-9, which rejected or accepted the statements/rationales, respectively; and (ii) the median score also lay within these ranges [14]. The type of consensus achieved was determined by the median score: "agreement" was defined for a median score \geq 7, and "disagreement" for a median score \leq 3. A median score within the 4–6 range meant that most of the group had scored the items as "uncertain."

Results

The panel was composed of a total of 18 experts, 4 methodologists, and 2 senior heads. The panel produced a total of 20 statements. The criteria for a consensus of agreement (i.e., a score in the range 7–9 provided by 75% or more of respondents, and a median score value also within this range) were met for 18 out of 20 statements in the first round of voting. Consensus was not achieved in relation to statements no. 5 and no. 17 (see Fig. S2, Additional file 2). After the second round of voting, consensus of agreement was achieved on all statements. The median score (plus interquartile range) and agreement percentage for all the statements contained in the final consensus report are shown in Fig. 1.

Clinical questions and consensus-based statements

A) Does LUS have a role to play in the diagnosis of COVID-19?

Statement 1: LUS should be integrated in the clinical workup to diagnose COVID-19 pneumonia. Statement 2: In patients with high clinical suspicion of COVID-19 and LUS findings compatible with ultrasonographic interstitial pneumonia, a negative nasal/oropharyngeal RT-PCR should not be used alone to exclude COVID-19.

Statement 3: LUS should not be used alone to rule in and rule out SARS-CoV-2 pneumonia in suspected COVID-19.

Lung ultrasound has been shown to improve the diagnostic accuracy in patients who present with acute respiratory symptoms [15]. The reliance on the clinical presentation of patients is a highly ineffective approach for COVID-19 case identification. The sensitivity of using crackles on auscultation for the detection of parenchymal involvement in COVID-19 patients was just 8% when compared to CT as reference [11]. On the contrary, LUS performs better than standard tests for dyspnea in the Emergency Department [16, 17], permitting COVID-19 pneumonia to be diagnosed in patients with normal vital signs [11], and distinguishing between viral and bacterial pneumonias [17]. LUS is more accurate

		ppropriate		Uncertain		10	propriate		Statement 11: LUS should be	or pre	one positionin	, pariell						
oes LUS have a role to p	ay in the diagn	osis of COVID-1	0?						integrated into the							_		
statement 1: LUS should be					\Box			$\neg \top$	assessment of patients considered potential							-	9	[
ntegrated in the clinical vorkup to diagnose COVID	.					-	—⊚)→	responders to prone									
9 pneumonia.									positioning, according to the focal and non-focal pattern									
Median score: 8.5 (IQR 7.5									of lung aeration loss.									
); Agreement: 17/18 94.44%)								_	Median score:8 (IQR:7-9);	1	2 3		4 5	5 6		7	8	9
	1	2 3	4	5	6	7	8	9	Agreement: 17/18 (94.44%) Statement 12: LUS can be						_			
									used to monitor variations in									
statement 2: In patients with righ clinical suspicion of								\neg	lung acration during prone positioning.								Y	
OVID-19 and LUS finding	s					_	-⊕-	→										
ompatible with ltrasonographic interstitial									Median score:9 (IQR:7-9); Agreement: 17/18 (94.44%)									
meumonia, a negative asal/oropharyngeal RT-PC	,				-				Agreement 17710 (741447.0)									
hould not be used alone to xclude COVID-19	`									1	2 3		4 5	5 6		7	8	9
	1	2 3	4	5	6	7	8	9										
Aedian score: 8 (IQR:7-9); Igreement:16/18 (88.89%)									Can LUS help early diagnosi ventilation?	s of pneumo	othorax in seve	re COVII)-19 patien	ts undergoi	ng invas	ive meci	hanical	
statement 3: LUS should no									Statement 13: LUS should be									
se used alone to rule out ARS-CoV-2 pneumonia in	1						6 _		used in COVID-19 patients,								<u> </u>	
ARS-CoV-2 pneumonia in uspected COVID-19.							9	_[in line with its clinical appropriateness as								9	
Aedian score:8 (IQR:8-9);									ascertained by studies in									
aeuun score:a (1910:a-9); Igreement: 17/18 (94.44%)									non-COVID-19 patients.									
									Median score:9 (IQR:8-9);									
	1	2 3	4	5	6	7	8	9	Agreement: 18/18 (100%)	1	2 3		4 5	5 6		7	8	9
	1		1						C IICLI I I I I			_		covan				
Can LUS help in the early	assessment of 6	COVID-19 severi	ty in the Em	ergency Depai	tment a	ind/or at IC	CU admissi	ion?	Can LUS help the early diagonechanical ventilation?	nosis of vent	tilator-associa	ted pneum	ionia in sev	ere COVID	-19 patie	ents und	tergoing	invasive
statement 4: Sonographic									Statement 14: LUS should be									
nultifocal and bilateral deural and lung					- 1	1	_	٦H	used in COVID-19 patients,							_		
bnormalities, a high overal .US score, and/or a high						•	-0	-	in line with its clinical appropriateness as								V	
core in the gravity								411	ascertained by studies in									
lependent areas can be used or the early assessment of					-+			+ + 1	non-COVID-19 patients.									
OVID-19 severity in the								$\exists \sqcup$	Median score:9 (IQR:7-9);									
mergency Department and t ICU admission since all	1	2 3	4	5 6	5	7	8	9	Agreement: 16/18 (88.89%)	1	2	. .	4 5	5 6		7	8	9
orrelate with worsening atient outcomes - intended		-													╧			
s the need for ICU	1								Can LUS help the process of	weaning s^	vere COVID	9 patient	from inve	sive mechan	ical ver	ilation?		
dmission, non-invasive entilation (NIV), intubation	,									caming se		. patients		c meendii	velli			
nd a higher mortality rate.	1		1		-+				Statement 15: We are unable to create any statement on								0	
Aedian score:8,5 (IQR:7-9)									the use of LUS in the assessment of patient								Y	_
Igreement:17/18 (94.44%)									readiness to sustain a									
									spontaneous breathing trial									
	1								(SBT). No study has evaluated the potential of									
									LUS for this purpose in COVID-19 nationts, and data	1	2 3		4 5	5 6		7	8	9
									in non-COVID-19 patients									
									are conflicting.									
	1																	
Can LUS be used as a lung	monitoring to	ol in COVID-19 p	patients und	ergoing non-in	vasive r	espiratory	support (F	HFNC,	Median score:8 (IOR:7-9):									
PAP, or NIV)?	monitoring to	ol in COVID-19	oatients und	ergoing non-in	vasive r	espiratory	support (F	HFNC,	Median score: 8 (IQR:7-9); Agreement: 14/18 (77.78%)									
CPAP, or NIV)? statement 5: In COVID-19 satients undergoing non-	monitoring to	ol in COVID-19	patients und	ergoing non-in	vasive r	respiratory	support (F	HFNC,	Median score:8 (IQR:7-9); Agreement:14/18 (77.78%) Statement 16: In association with standard clinical and							L		
CPAP, or NIV)? statement 5: In COVID-19 statement standergoing non- nvasive respiratory support HFNC, CPAP or NIV), LU	T	ol in COVID-19 p	patients und	ergoing non-in	vasive r	respiratory	support (F	HFNC,	Median score:8 (IQR:7-9); Agreement:14/18 (77.78%) Statement 16: In association with standard clinical and physiological indexes, LUS							<u> </u>	_) -
EPAP, or NIV)? statement 5: In COVID-19 statients undergoing non- nvasive respiratory support HFNC, CPAP or NIV), LU ntegrated with clinical and	T	ol in COVID-19	patients und	ergoing non-in	vasive r	respiratory	support (F	HFNC,	Median score:8 (IQR:7-9); Agreement: 14/18 (77.78%) Statement 16: In association with standard clinical and physiological indexes, LUS can improve the prediction of SBT outcome in COVID-19							•		>
CPAP, or NIV)? statement 5: In COVID-19 statemts undergoing non- nussive respiratory support HFNC, CPAP or NIV), LU ntegrated with clinical and shysiological parameters nay contribute to predict	T	ol in COVID-19	patients und	ergoing non-in	vasive r	respiratory	support (F	HFNC,	Median score:8 (IQR:7-9); Agreement:14/18 (77.78%) Statement 16: In association with standard clinical and physiological indexes, LUS can improve the prediction of							•	_	>
PAP, or NIV)? statement 5: In COVID-19 statement 5: In COVID-19 statement 5: In COVID-19 statement 5: In COVID-19 HENC, CPAP or NIV), LU ntegrated with clinical and hysiological parameters nay contribute to predict on-invasive respiratory upport outcome and early upport outcome and early	T	ol in COVID-19	patients und	ergoing non-in	vasive r	espiratory	support (F	HFNC,	Median score:8 (IQR:7-9); Agreement:14/18 (77.78%) Statement 16: In association with standard elimical and physiological indexes, LUS can improve the prediction of SBT outcome in COVID-19 patients. Median score: 8,5 (IQR 7-									Э
CPAP, or NIV)? statement 5: In COVID-19 statemts undergoing non- nussive respiratory support HFNC, CPAP or NIV), LU ntegrated with clinical and shysiological parameters nay contribute to predict	T	ol in COVID-19 p	patients und		vasive r	respiratory	support (F	HFNC,	Median score:8 (IQR:7-9); Agreement:14/18 (77.78%) Statement 16: In association with standard clinical and physiological indexes, LUS can improve the prediction of SBT outcome in COVID-19 patients.	1	2 3		4 5	5 6		7	8	3
PAP, or NIV)? statement 5: In COVID-19 statement 5: In COVID-19 autients undergoing non- nvasive respiratory support HFNC, CPAP or NIV), LU ntegrated with clinical and hysiological parameters nay contribute to predict non-invasive respiratory upport outcome and early letect complications. Aedian score: 8 (IQR:7.5-	T					-	0		Median score: 8 (IQR:7-9): Agreement: I4/18 (77:78%) Statement 16: In association with standard clinical and physiological indexes, LUS can improve the prediction of SBT outcome in COVID-19 patients. Median score: 8,5 (IQR:7-9): Agreement: 17/18 (94.44%)	1	2 3		4 5	6 6		7	8	9
PAP, or NIV)? statement 5: In COVID-19 statement 5: In COVID-19 statement sundergoing non- nvasive respiratory support HFNC, CPAP or NIV), LU ntegrated with clinical and shysiological parameters may contribute to predict on-invasive respiratory upport outcome and early lettect complications.	T					-	0		Median score 8 (IQR-7-9); Agreement IL/18 (77.78%) Statement 10: In association physiological indexes, LUS can improve the prediction of SBT outcome in COVID-19 patients. Median score: 8.5 (IQR 7- 9); Agreement: 17/18 Statement 17: In association with standard clinical and	1	2 3	; ,	4 5	5 6		7	8	_
PAP, or NIV)? statement 5: In COVID-19 statement 5: In COVID-19 statement signification on- massive respiratory support harmonic support ha	T					-	0		Median scores (1QR 7-9). **Geometric UTB 777-78%) **Section of the Processing of t	1	2 3		4 5	6		7	8	9
PAP, or NIV)? statement 5: In COVID-19 statement 5: In COVID-19 statement signification on- massive respiratory support harmonic support ha	1	2 3	4	5	6	7	8		Median score'S (IQE 7-9); Agreement 1618 17:7759; Median score'S (IQE 7-9); Median score 1618 17:7759; Median score 1618 17:7759; Median score 8.5 (IQE 7-9); Median score 17: In association with standard clinical and sown than standard clinical and score 17: In association of the score 17: In association	1	2 3		4 5	5 6		7	8	_
PAP, or NNY? Waternem S: In COVID-19 satients undergoing non- massive respiratory support HFNC, CPAP or NIV), LU satients undergoing non- massive respiratory support HFNC, CPAP or NIV), LU satients and satients and satients hysiological parameters any contribute to predict upport outcome and early letect complications. declaim score: 8 (IQR-7.5-); [greement: 18/18 (100%) Can LUS be used as a lung statement 6: LUS should be	1	2 3	4	5	6	7	8		Median score 8 (IQR-7-9); <u>Agreement: IV18 (77.78%)</u> Statement 16: In association with standard clinical and of the standard clinical and of the standard o	1	2 3		4 5	5 6		7	8	_
PAP, or NNy? statement 5: In COVID-19 uniters undergoing non- massive respiratory support HFNC, CPAP or NIV), LU massive respiratory support HFNC, CPAP or NIV), LU may contribute to predict on-invasive respiratory upport outcome and upport outcome and puport outcome and upport outcome and dealin score: 8 (IQR:7.5- ig/greement: I&I8 (100%) an LUS be used as a lung statement 6: LUS should be integrated into the	1	2 3	4	5	6	7	8		Median score'S (IQE: 7-9). Speciment LEIS (T7: 725). Speciment LEIS (T7: 725). Speciment LEIS (T7: 725). With standard clinical and physiological indexes, LUS can improve the prediction of SIT outcome in COVID-19 patients. Median score: 8.5 (IQE: 7-9). Speciment T7: The succession of the proposition of the propositi	1	2 3		4 5	6 6		7	8	_
PAP, or NN)? Statement 5: In COVID-19 uniters undergoing non- massive respiratory support HFNC, CFAP or NN), LI, una vassive respiratory support HFNC, CFAP or NN), LI, uniterating to the clinical and una contribution to predict so-invasive respiratory upport outcome and early telect complications. Action score: 8 (IQR:7.5-). Igreement: IST8 (109%) Tan LUS be used as a lung tattement 6: LIS should be magnited into his control of the control of the country tattement for the country of the country tattement for LIS should be magnited into the sissesse progression and the	1	2 3	4	5	6	7	8		Median score's (IQR: 7-9); Agreement 16 18 77: 759; Subtream 16 10 a sociation Subtream 16 in association physiological indexes, LUS can improve the prediction of SIT outcome in COVID-19 patients. Median score: \$5 (IQR: 7- 92-Agreement: 17/18 (94.44%) Statement 17: In association with standard clinical and physiological indexes, LUS can improve the prediction of exclusions failure in COVID-19 patients.	1	2 3		4 5			7	8	_
PAP, or NN)? Statement 5 in CVIID-19 utatients undergoing nore massive respiratory support survive respiratory support survive respiratory support survive respiratory support outcomes and carly support outcome and carly support outcomes support outcomes and support outcomes and support sup	1	2 3	4	5	6	7	8		Median score'S (IQE: 7-9). Speciment LEIS (T7: 725). Speciment LEIS (T7: 725). Speciment LEIS (T7: 725). With standard clinical and physiological indexes, LUS can improve the prediction of SIT outcome in COVID-19 patients. Median score: 8.5 (IQE: 7-9). Speciment T7: The succession of the proposition of the propositi									-0
PAP, or NN)? Statement 5: In COVID-19 uniters undergoing non- massive respiratory support HFNC, CFAP or NN), LI, una vassive respiratory support HFNC, CFAP or NN), LI, uniterating to the clinical and una contribution to predict so-invasive respiratory upport outcome and early telect complications. Action score: 8 (IQR:7.5-). Igreement: IST8 (109%) Tan LUS be used as a lung tattement 6: LIS should be magnited into his control of the control of the country tattement for the country of the country tattement for LIS should be magnited into the sissesse progression and the	1	2 3	4	5	6	7	8		Median score's IQER-79, Agreement 1618 17.758, Median Service 1818 17.758, Median Service 1818 17.758, With Standard Intolical and physiological indexes, LUS can improve the prediction of SHT outcome in COVID-19 patients. Median score: 8.5 IQER 79, Agreement 17: In association with standard clinical and physiological indexes, LUS Statement 17: In association with standard clinical and physiological indexes, LUS of extra clinical and physiological indexes, LUS of extra clinical and physiological indexes, LUS of extra clinical and physiological indexes, LUS Statement 17: In association with standard clinical and physiological indexes, LUS (SAS) Median score: 9 IQER-79, Agreement: 16/18 (SAS) Median score: 9 IQER-79, Median	1	2 3		4 5	5 6				-0
PAP, or NN)? Institute undergoing non- monopolity of the particle of the part	1 monitoring to	2 3	4	5	e mech:	7	8 stilation?	9	Median score's (IQR: 7-9); Agreement 1618 (77.78); Median score's (IQR: 7-9); Median score in the scale and physiological indexes, LUS on improve the prediction of SIT outcome in COVID-19 patients. Median score: 8.5 (IQR: 7); Median score: 8.5 (IQR: 7); Median score: 8.5 (IQR: 7); Median score in the prediction of six of the prediction of six of the prediction of six of the prediction of the standard clinical and physiological indexes, LUS an improve the prediction of 19 patients. Median score: 9 (IQR: 7-9); Agreement: 1618 (88.89%) Can LUS decrease the need f	1	2 3		4 5	5 6				-0
PAP, or NN)? Statement 5: In COVID-19 unitarist undergoing non-wavier registratory support on the control of the covid of	1	2 3	4	5	6	7	8		Median score'S (IQE: 7-9). Speciment LEIS (T7: 725). Speciment LEIS (T7: 725). Speciment LEIS (T7: 725). Median score is a speciment LEIS (T7: 725). Median score: A5 (IQE: 7-9). Median score: A5 (IQE: 7-9). Agreement 17: In succiation with standard chinical and physiological indexes, LUS can improve the prediction of strubution falliur in COVID—19 patients. Median score: B(IQE: 7-9). Agreement: 16:18 (88:89%). Can LUS decrease the need f Statement 18: In patients	1	2 3		4 5	5 6				9
PAP, or NN)? Interest and a proper properties of the properties o	1 monitoring to	2 3	4	5	e mech:	7	8 stilation?	9	Median score's IQEE-79; Agreement 1618 17:7759; Median score's IQEE-79; Agreement 1618 17:7759; Median score 1618 17:7759; Median score 8:5100 17:7759; Median score 8:5100 17:78 Statement 17: In association with standard clinical and only the score 17: In association with standard clinical and only the score 17: In association with standard clinical and only the score 17: In association of the score 17: In asso	1	2 3		4 5	5 6				-0
PAP, or NN)? Interest undergoing more management of the property of the prope	monitoring to	2 3	4	5	e mech:	7	8 stilation?	9	Medium wore's (1/08:-9). Medium wore's (1/08:-9). Medium wore's (1/08:-1). Medium distributional and physiological indexes, LUS can improve the prediction of SIT outcome in COVID-19 patients. Medium wore & 3 (1/08: 7). Medium wore & 5 (1/08: 7). Medium wore & 5 (1/08: 7). Medium wore & 5 (1/08: 7). Medium wore & 1/08: 7.9). Medium wore or 9 (1/08:-9). Agreement: 16/18 (88:49%) Can LUS decrease the need of Statement 18: In patients with known COVID-19 under the support of	1	2 3		4 5	5 6				9
PAP, or NN)? The property of	monitoring to	2 3	4	5	e mech:	7	8 stilation?	9	Median score 8 (IQE 7-9). Secrement LVI 8 (77.795) Secrement LVI 8 (77.795) Secrement LVI 8 (77.795) Median score 8 (1987) Secrement LVI 9 (1987) Secrement	1	2 3		4 5	5 6				9
PAP, or NN)? Interest undergoing new-power and acceptance of the property of	monitoring to	2 3	4	5	e mech:	7	8 stilation?	9	Median score \$1(0)87-9). Marenment UP 177.1874. Statement 16 In ascociation with standard clinical and physiological indexes, LUS can improve the prediction of 50 parties. Median score \$5.7(0)8.7 parties. Median score \$1.7(0)8.7 parties. Can LUS decrease the need score	1	2 3		4 5	5 6				9
PAP, or NN)? Institute undergoing nor- more convergence of the conver	monitoring to	2 3	4	5	e mech:	7	8 stilation?	9	Medium wore's 1(1987-9). Medium wore's 1(1987-1991). Medium and the Medium and physiological indexes, LUS can improve the prediction of SIT outcome in COVID-19 palents. Medium wore & 5 (10) 8.7. Medium wore & 5 (10) 8.7. Medium wore & 5 (10) 8.7. Statement 17.18 (84.489). Statement 17.18 association with standard clinical and physiological indexes, LUS can improve the prediction of evolution failing in COVID-19 palents. Medium wore or 9 (10) 8.7.9. Agreement: 16/18 (88.89%) Can LUS decrease the need f Statement 18. In patients with two-in COVID-19 and should be performed insetted of radiologic chest imaging as the first-line imaging test to momitter disease.	1	2 a	g in sever	4 5	5 6		7	8	9
PAP, or NN)? attacked by the control of the contro	monitoring to	2 3	4	5 sergoing invasiv	e mech:	7	8 stilation?	9	Median score \$1(0)87-9). Marenment UP 177.1874. Statement 16 In ascociation with standard clinical and physiological indexes, LUS can improve the prediction of 50 parties. Median score \$5.7(0)8.7 parties. Median score \$1.7(0)8.7 parties. Can LUS decrease the need score	1	2 3	g in sever	4 5	5 6				9
PAP, or NN)? Institute undergoing non- monotonic production and engine group migrated with clinical and hypothesis and any contribute to predict any post production and any post production and any post production and any post production and any post outcome and purport pu	monitoring to	2 3 3 all in COVID-19 p	a a satients unde	5 sergoing invasiv	of 6	7	8 8	9	Statement 19 in account of the CVID-19 parties. Medium court & GOVID-19 parties of the CVID-19 parties of the CVID-19 parties of the CVID-19 parties of the CVID-19 parties. Medium court & GOVID-19 parties of the CVID-19 parties. Medium court & GOVID-19 parties of the CVID-19 parties. Medium court & GOVID-19 parties of the CVID-19 parties. Medium court & GOVID-19 parties of the CVID-19 parties. Medium court & GOVID-19 parties of the CVID-19 parties. Statement 15 fa Statement 18 parties of the CVID-19 parties. Statement 18 parties of the CVID-19 parties of the CVID-19 parties. Statement 18 parties of the CVID-19 parties of the C	1	2 a	g in sever	4 5	5 6		7	8	9
PAP, or NN)? attained and provided and advantage and adva	monitoring to	2 3 3 all in COVID-19 p	a a satients unde	5 sergoing invasiv	of 6	7	8 8	9	Median score'S (IQE: 7-9). Agreement LIB (17: 778-5). Median score S (IQE: 7-9). Median score S (IQE: 7-10). Statement T: In association with standard clinical and physiological induces. LUS can improve the prediction of statement of the score of the s	1	2 a	g in sever	4 5	5 6		7	8	9
PAP, or NN)? The property of	1 monitoring to	2 3 3 all in COVID-19 p	a a satients unde	5 sergoing invasiv	of 6	7	8 8	9	Median score'S (IQE 7-9); Mercoment 1618 (77.75); Mercoment 1718 (78.45); Mercoment 1618 (78.65); Merc	1	2 a	g in sever	4 5	5 6		7	8	9
PAP, or NN)2 attents undergoing nore particular that the property of the prop	1 monitoring to	2 3 3 all in COVID-19 p	a a satients unde	5 sergoing invasiv	of 6	7	8 8	9	Median score 5 (10): 7-9). Median score 5 (10): 7-10. Statement 16 in accounting the second score and physiological indexes, LUS can improve the prediction of SIT outcome in COVID-19 pallents. Median score 5.3 (10): 7-10. Median score 5.3 (10): 7-10. Statement 17: 18 association with standard clinical and physiological indexes, LUS can improve the prediction of physiological indexes, LUS can improve the prediction of the standard clinical and physiological indexes, LUS can improve the prediction of the standard clinical and physiological indexes, LUS can improve the prediction of the standard clinical and physiological indexes, LUS can improve the prediction of the standard clinical section of the standard clini	1	2 a	g in sever	4 5	5 6		7	8	9
PAP, or NN)? The property of	1 monitoring to	2 3 3 all in COVID-19 p	a a satients unde	5 sergoing invasiv	of 6	7	8 8	9	Median score 5 (10): 7-9. Median score 5 (10): 7-19. Median score 10: 10: 10: 10: 10: 10: 10: 10: 10: 10:	1	2 a	g in sever	4 5	5 6		7	8	9
PAP, or NN)? attacked by the property of the	1 monitoring to	2 3 3 all in COVID-19 p	a a satients unde	5 sergoing invasiv	of 6	7	8 8	9	Statement 15 in 2017 18 patients with story of 100 to 100	1	2 :	ig in sever	4 5 e COVID-1	5 6 19 patients?		7	8	9
PAP, or NN)? attained and provided and analysis growth analys	nonitoring to	2 3 a solution of the covid-19 graphs of the	a alients und	5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7	8	9 9	Medium wore's (1/08:7-9). Medium wore's (1/08:7-0). Stemman 16: In accounting with standard clinical and physiological Indexes, LUS can improve the prediction of SIT outcome in COVID-19 palicins. Medium wore 8.5 (1/08:7-7). Medium wore 8.5 (1/08:7-7). Statement 17: In association with standard clinical and physiological Indexes, LUS can improve the prediction of evuluation failure in COVID-19 palicins. Medium wore 9 (1/08:7-9). Agreement 16/18 (88:89%) Can LUS decrease the need Statement 16/18 (88:89%) Can LUS decrease the need Statement 16/18 (88:89%). Can LUS decrease the need Statement 16/18 (88:89%). Medium wore 9 (1/08:8-9). Medium wore 9 (1/08:8-9). Medium wore 16/18 (88:89%) Statement 19/11 LUS findings with the standard of radiologic chest imaging as the finst-line imaging test in monitor disease progression. Medium wore 9 (1/08:8-9). Medium wore 9 (1/08:8-9). Medium wore 16/18 (88:89%) Statement 19/11 LUS findings with the standard and individual maging techniques unnecessary expectally when the likelihood of an alternative diagnosts is found.	1	2 a	ig in sever	4 5 e COVID-1	5 6		7	8	9
PAP, or NN)? attacked by the property of the	1 monitoring to	2 3 3 all in COVID-19 p	a a satients unde	5 5	of 6	7	8 8	9	Statement 12 in association with standard clinical and physiological indexes, LUS can improve the prediction of particular and physiological indexes, LUS can improve the prediction of particular and properties of particular and properties of particular and physiological indexes, LUS can be provided by the properties of the particular and physiological indexes, LUS can be provided by the provided by the provided by particular indexes and provi	1	2 :	ig in sever	4 5 e COVID-1	5 6 19 patients?		7	8	9
PAP, or NN)2 attents undergoing nore management 5 in COVID-19 attents undergoing nore management 6 in COVID-19 attents undergoing nore management 7 in Covid-19 attents under 6 in Covid-19 attention of the State of the Covid-19 attention of the Covid-19 atte	nonitoring to	2 3 a solution of the covid-19 graphs of the	a alients und	5 5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7	8	9 9	Median score 5 (10): 7-9). Median score 5 (10): 7-10. Statement 16 in accounting the second score and physiological indexes, LUS can improve the prediction of SIT outcome in COVID-19 palicins. Median score 5.3 (10): 7-10. Median score 5.3 (10): 7-10. Statement 17: 18 association with standard clinical and physiological indexes, LUS can improve the prediction of physiological indexes, LUS can improve the prediction of the production of	1	2 :	ig in sever	4 5 e COVID-1	5 6 19 patients?		7	8	9 9
FAP, or NNY2 attained the COVID-19 attained	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 3 a solution of the covid-19 graphs of the	a alients und	5 5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7	8	9	Median score'S (IQE: 7-9). Mercoment LUB (17: 778-5). Mercoment LUB (17: 778-5). Mercoment LUB (17: 778-5). Mercoment LUB (17: 778-5). Median score & IQE (18: 78-5). Median score & IQE (18: 79-5). Median score & IQE (18: 79-5). Mercoment LUB (18: 78-5). Statement T: In association with standard clinical and physiological indexes, LUS can improve the prediction of extubation fallaries. Median score & IQE (19: 79-1). Median score & IQE (19: 79-1). Mercoment IS In patients with Known COVID-19 and severe symptoms, LUS should be performed instead severe symptoms, LUS should be performed instead as the first-line tanging text to monitor disease progression. Median score & IQE (19: 8-9). Median score & IQE (19: 8-9). Mercoment IS ILIS findings. Statement IS In migration to median diditional imaging text to monitor disease progression. Median score & IQE (19: 8-9). Mercoment IS IRI (18: 88-78). Median score & IQE (19: 8-9). Mercoment IS IRI (18: 88-78). Median score & IQE (19: 8-9). Median score & IQE (19: 8-9). Mercoment IS IRI (18: 88-88-1). Median score & IQE (19: 8-9).	1	2 :	ig in sever	4 5 e COVID-1	5 6 19 patients?		7	8	9
PAP, or NN)? The property of	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 3 a solution of the covid-19 graphs of the	a alients und	5 5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7	8	9	Statement 15 in patients with Novo COVID-19 and Serversens 15 in Section	1	2 :	ig in sever	4 5 e COVID-1	5 6 19 patients?		7	8	9 9
FAP, or NNY2 attained the COVID-19 attained	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 3 a solution of the covid-19 graphs of the	a alients und	5 5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7	8	9	Medium wore's 1(19:8-79). Medium wore's 1(19:8-7) that the state of the social and physiological indexes, LUS can improve the prediction of SIT outcome in COVID-19 palestes. Medium wore 8.5 (10):7.7 palestes. Medium wore 8.5 (10):7.7 palestes. Statement 17:18 socialism with standard clinical and physiological indexes, LUS can improve the prediction of physiological indexes, LUS can improve the prediction of exubations failure in COVID-19 palestes. Medium wore 9 (10):7.9 palestes. Can LUS decrease the need Statement 18:18 papieras which was a statement 19:18 findings as the first-line imaging test to monitor disease progression. Medium wore 9:10(28:8-9). Medium wore 8:16 (28:8-9). Medium wore 8:5 (10):18:19:19:19:19:19:19:19:19:19:19:19:19:19:	1	2 :	ig in sever	4 5 e COVID-1	5 6 19 patients?		7	8	9 9
PAP, or NN)? Interest undergoing near-outer designation of the property of th	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 3 a solution of the covid-19 graphs of the	a alients und	5 5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7	8	9	Median score'S (IQE: 7-9). Secrement LVI & 177-75-15 Secrement LVI & 177-75-75 Secrement LVI & 177-75	1	2 :	ig in sever	4 5 e COVID-1	5 6 19 patients?		7	8	9 9
PAP, or NN)? The property of	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 3 a solution of the covid-19 graphs of the	a alients und	5 5 5 5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7	8	9	Median score 8 (10):87-99. Median score 8 (10):87-109. Statement 16 in account on with standard clinical and physiological indexes, LUS can improve the prediction of SIT outcome in COVID-19 patients. Median score 8.5 (10):87-79 patients. Median score 8.5 (10):87-79 patients. Statement 17:18 association with standard clinical and physiological indexes, LUS can improve the prediction of the patients. Median score 9 (10): 18-29; Agreement 16-18 findings to the first-line impriging techniques unsecessary, especially when the incellibod of an alternative diagnosis is inc. Median score 9 (10): 8.39; Agreement 15-18 findings techniques unsecessary, especially when the incellibod of an alternative diagnosis is inc. Median score 5 (10): 8.39; Agreement 15-18 findings techniques unsecessary, especially when the incellibod of an alternative diagnosis is inc.	1	2 :	ig in sever	4 4 5 6 COVID-D	5 6 6 5 6 6		7 7 7	8	9 9
PAP, or NN)? attained a More and	nonitoring to	2 3 3 3 2 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3	a a a a a a a a a a a a a a a a a a a	5 5 5 5 5 5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	8 8 8 8 8 8 8 8	9 9	Median score'S (IQE: 7-9). Secrement LVI & 177-75-15 Secrement LVI & 177-75-75 Secrement LVI & 177-75	1	2 :	ig in sever	4 5 e COVID-1	5 6 6 5 6 6		7	8	9 9
PAP, or NN)? attacked a statement 5 in CVIII-19 attacked and engage growing and a statement a	nonitoring to	2 3 3 3 2 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3	a a a a a a a a a a a a a a a a a a a	5 5 5 5 5 5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	8 8 8 8 8 8 8 8	9 9	Median score'S (IQE: 7-9). Secrement LVI & 177-75-15 Secrement LVI & 177-75-75 Secrement LVI & 177-75	1	2 :	ig in sever	4 4 5 6 COVID-D	5 6 6 5 6 6		7 7 7	8	9 9
PAP, or NN)2 attained and the CVIII-19 attained and proper has been dependent on the CVIII-19 attained and proper has been dependent on the CVIII-19 and	nonlitering to	2 3 3 3 2 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3	a a a a a a a a a a a a a a a a a a a	5 5 5 5 5 5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	8 8 8 8 8 8 8 8	9 9	Median score'S (IQE: 7-9). Secrement LVI & 177-75-15 Secrement LVI & 177-75-75 Secrement LVI & 177-75	1	2 :	ig in sever	4 4 5 6 COVID-D	5 6 6 5 6 6		7 7 7	8	9 9
PAP, or NNY2 attained the COVID-19 attained	nonlitering to	2 3 3 3 2 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3	a a a a a a a a a a a a a a a a a a a	5 5 5 5 5 5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	8 8 8 8 8 8 8 8	9 9	Median score'S (IQE: 7-9). Secrement LVI & 177-75-15 Secrement LVI & 177-75-75 Secrement LVI & 177-75	1	2 :	ig in sever	4 4 5 6 COVID-D	5 6 6 5 6 6		7 7 7	8	9 9
PAP, or NN)? Statement 5. In CVIII-19 attents undergoing non- positions undergoing non- positions undergoing non- positions undergoing non- position of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of propert	nonlitering to	2 3 3 3 2 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3	a a a a a a a a a a a a a a a a a a a	5 5 5 5 5 5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	8 8 8 8 8 8 8 8	9 9	Median score'S (IQE: 7-9). Secrement LVI & 177-75-15 Secrement LVI & 177-75-75 Secrement LVI & 177-75	1	2 :	ig in sever	4 4 5 6 COVID-D	5 6 6 5 6 6		7 7 7	8	9 9
PAP, or NN)? attained a Montagoing nore particular that and a management of the particular that a management of the malifirmodal assessment of the particular that a management of the multimodal assessment of the particular that a management of the multimodal assessment of the particular that a management of the multimodal assessment of the particular that a management of the multimodal assessment of the particular that a management of the partic	nonlitering to	2 3 3 3 2 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3	a a a a a a a a a a a a a a a a a a a	5 5 5 5 5 5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	8 8 8 8 8 8 8 8	9 9	Median score'S (IQE: 7-9). Secrement LVI & 177-75-15 Secrement LVI & 177-75-75 Secrement LVI & 177-75	1	2 :	ig in sever	4 4 5 6 COVID-D	5 6 6 5 6 6		7 7 7	8	9 9
PAP, or NN)? attained and adopting more partial attained and adopting the partial attained and adopting more partial attained and additional account and adopting more partial attained and additional a	nonlitering to	2 3 3 3 2 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3	a a a a a a a a a a a a a a a a a a a	5 5 5 5 5 5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	8 8 8 8 8 8 8 8	9 9	Median score'S (IQE: 7-9). Secrement LVI & 177-75-15 Secrement LVI & 177-75-75 Secrement LVI & 177-75	1	2 :	ig in sever	4 4 5 6 COVID-D	5 6 6 5 6 6		7 7 7	8	9 9
PAP, or NN)? attained a Montagoing nore particular that and a management of the particular that a management of the malifirmodal assessment of the particular that a management of the multimodal assessment of the particular that a management of the multimodal assessment of the particular that a management of the multimodal assessment of the particular that a management of the multimodal assessment of the particular that a management of the partic	nonlitering to	2 3 3 3 2 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3	a a a a a a a a a a a a a a a a a a a	5 5 5 5 5 5 5	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	8 8 8 8 8 8 8 8	9 9	Median score'S (IQE: 7-9). Secrement LVI & 177-75-15 Secrement LVI & 177-75-75 Secrement LVI & 177-75	1	2 :	ig in sever	4 4 5 6 COVID-D	5 6 6 5 6 6		7 7 7	8	9 9

Fig. 1 The median score (plus interquartile range) and agreement percentage for all the statements contained in the final consensus report

than chest X-ray in diagnosing respiratory conditions [18, 19], including interstitial diseases [20], pneumonia [21], and COVID-19 pneumonia [22]. If the pre-test probability of COVID-19 is low [23], a LUS bilateral Apattern with sliding makes COVID-19 pneumonia unlikely owing to its high negative predictive value for pneumonia [24, 25]. The strong correlation between CT and LUS scans in COVID-19 patients supports the preferential use of LUS over CT in scenarios where CT is inappropriate (e.g., pregnancy) or difficult to obtain [26]. Real-time polymerase chain reaction (RT-PCR) testing is currently the standard diagnostic test for SARS-CoV-2 infection, and it is reported to have high specificity but only moderate sensitivity for diagnosing COVID-19 [27, 28]. Coupled with pre-test probability, bilateral B-lines, an irregular pleural line, and sub-pleural consolidations increase the likelihood of COVID-19 diagnosis [29, 30]. A recent meta-analysis of six observational studies and a case series describing a total of 122 symptomatic patients highlights the role of LUS in the diagnosis of COVID-19 [31]. Interstitial lung involvement, depicted by the B-pattern, was the most common and consistent finding by LUS, and the presence of this finding in addition to other characteristic symptoms will increase the likelihood of diagnosis. The "light beam" artifact is a LUS sign that corresponds to the early appearance of "ground-glass" opacity on a CT scan, and it has been observed in most patients with COVID-19 pneumonia [32, 33]. Some authors have suggested the "light beam" sign to be specific to COVID-19 pneumonia, and its presence may increase the diagnostic likelihood in patients suspected of having COVID-19 [1]. However, LUS should always be integrated into a more comprehensive clinical evaluation, and LUS findings should be interpreted in light of the pre-test probability of COVID-19 pneumonia.

B) Can LUS help in the early assessment of COVID-19 severity in the Emergency Department and/or at ICU admission?

Statement 4: Sonographic multifocal and bilateral pleural and lung abnormalities, a high overall LUS score, and/or a high score in the gravity dependent areas can be used for the early assessment of COVID-19 severity in the Emergency Department and at ICU admission since all correlate with worsening patient outcomes—intended as the need for ICU admission, non-invasive ventilation (NIV), intubation, and a higher mortality rate—although ICU admission still remains a clinical decision based on clinical assessment and some related exams.

Several observational prospective cohort studies of COVID-19 patients have found a significant correlation between LUS findings and poor outcome, defined as ICU admission, increased likelihood of acute respiratory failure, the need for non-invasive or invasive mechanical ventilation, and a higher hospital mortality rate [34, 35]. In all these studies, LUS scores were based on a 4-level scoring system ranging from 0 to 3, but they differed in the number of areas scanned, which ranged from 6 to 14 lung regions [34-55]. Two groups of researchers analyzed the agreement between the different LUS score protocols and patient outcome in COVID-19 patients and concluded that, independently of the number of areas scanned, the accuracy in outcome prediction was higher when the protocol adopted included the evaluation of the gravity dependent areas [44, 45]. One case series and sixteen observational prospective cohort studies have provided consistent results suggesting that, independently of the protocol adopted, a moderate loss of aeration as assessed by LUS is associated with a higher need for NIV, whereas a severe loss of lung aeration is associated with an increased likelihood of ICU admission and mortality [34-41, 43-49, 51, 54]. In five observational prospective studies [40–42, 54, 55], an increased likelihood of NIV failure was associated with a severe loss of lung aeration as assessed by the LUS score, independently of the protocol adopted. In the light of this evidence, and independently of the number of areas scanned and the LUS score protocol adopted, the presence of sonographic multifocal and bilateral pleural and lung abnormalities together with a high overall LUS score and/or high scores in the gravity dependent areas may help in predicting NIV failure, the need for ICU admission, and hospital mortality in the emergency room. The 12-lung-region scoring system usually adopted in critically ill patients is described in Fig. 2.

C) Can LUS be used as a lung monitoring tool in COVID-19 patients undergoing non-invasive respiratory support (HFNC, CPAP, or NIV)?

Statement 5: In COVID-19 patients undergoing non-invasive respiratory support (HFNC, CPAP, or NIV), LUS integrated with clinical and physiological parameters may contribute to predict non-invasive respiratory support outcome and early detect complications.

Although robust evidence in COVID-19 patients has yet to be gathered, apart from some interesting case series [56, 57] and a few observational cohort studies involving small sample sizes [58, 59], the role of LUS as a monitoring tool in the field of interstitial lung diseases has already been confirmed since the LUS score is



Fig. 2 The lung ultrasound score (LUS) can be applied to assess the loss of aeration by dividing the thorax into 12 specific regions, six on the right and six on the left in supine or prone position assign each region a score from 0 (normal lung) to 3 (lung consolidation). Anterior, lateral, and posterior fields are identified by sternum, anterior, and posterior axillary lines. The entire examination can be performed without any change in patient's position. Score: 0 = normal aeration (A-lines and lung sliding or maximum 2 well-spaced B-lines); score 1 = moderate loss of aeration (> = 3 well-spaced B-lines with lung sliding, coalescent B-lines/subpleural consolidations occupying < 50% of the pleural line); score 2 = severe loss of aeration (> = 3 well-spaced B-lines with lung sliding, coalescent B-lines/subpleural consolidations occupying clearly > 50% of the pleural line); score 3 = complete loss of aeration: lobar/hemilobar consolidation with predominant tissue like pattern

known to correlate with lung aeration [60]. Based on all the evidence available in this setting [37, 39-41, 43, 49, 54, 56, 58], the daily assessment of the LUS score in COVID-19 patients undergoing non-invasive respiratory support can be considered an appropriate approach. A worsening overall LUS score, with or without a high LUS score in the gravity dependent areas, may be predictive of a worsening patient outcome and the failure of a 24-h non-invasive respiratory support trial [40-42, 54, 56]. On the other hand, a stable or decreasing overall LUS score after a 24-h non-invasive respiratory support trial, together with an improvement in the LUS score in the gravity dependent areas, may be associated with non-invasive respiratory support success. Furthermore, pneumothorax (PNX) and pneumomediastinum are common complications in severe COVID-19 respiratory failure [61, 62], even in patients undergoing non-invasive ventilation, especially if associated with exacerbating inspiratory efforts and high pleural pressure swings. The role of LUS in the early detection and monitoring of PNX is well-known. In fact, the sensitivity and specificity of LUS for the detection of even small occult PNX have been demonstrated to be high [63, 64]. In patients without subcutaneous emphysema, pneumomediastinum may be suspected once PNX has been ruled out in the presence of specific ultrasound findings in the subxiphoid view and/or in the anterolateral cervical region [65, 66].

D) Can LUS be used as a lung monitoring tool in COVID-19 patients undergoing invasive mechanical ventilation?

Statement 6: LUS should be integrated into the multimodal assessment of disease progression and the response to treatments in mechanically ventilated COVID-19 patients.

Statement 7: LUS should be integrated into the clinical decision-making process and monitoring of procedures, such as fibrobronchoscopy, in mechanically ventilated COVID-19 patients.

Statement 8: LUS should be integrated into the clinical decision-making process and monitoring of treatments, such as antibiotics, in mechanically ventilated COVID-19 patients.

Statement 9: LUS should be integrated into the clinical decision-making process and monitoring of fluid removal in mechanically ventilated COVID-19 patients.

Specific ultrasound findings provide useful information for the monitoring of mechanically ventilated patients [60, 67]. A complete examination requires only a few minutes and shows high inter-observer agreement even with ultra-portable devices [8-68]. Changes in the LUS score over time may help the assessment of disease progression and of the response to treatments in ARDS patients [69-72]. Monitoring the lung with LUS may improve the management of fluid balance in acute respiratory failure patients [73, 74]. The visualization of a newly appeared tissue-like pattern could point toward/ be suggestive of reabsorption at lectasis (if a static or absent air-bronchogram is visualized) [75], ventilatorassociated pneumonia (dynamic linear/arborescent airbronchogram), or lung collapse with patent airways (dynamic punctiform air-bronchogram), thus indicating the need for dis-obstructive fibro-bronchoscopy, distal micro-biological sampling, or titration of positive pressure mechanical ventilation [76]. Pleural line assessment is also of interest in COVID-19 patients. The results of an in vitro study suggest that the persistence of subpleural consolidations and pleural irregularities may be a marker of fibro-proliferative diffuse alveolar damage [77]; in fact, these signs are observed in vivo at admission in patients with long-duration symptoms [78]. When combined with suggestive clinical parameters and compressive vein ultrasound, the presence of large subpleural consolidations are associated with a high probability of pulmonary embolism [79].

E) Can LUS guide the titration of positive end expiratory pressure in severe COVID-19 patients receiving invasive mechanical ventilation?

Statement 10: LUS should be considered as an additional tool for PEEP titration in COVID-19.

The limitations of LUS as a tool for titrating PEEP levels in COVID-19 patients are the same as those applying to ARDS patients, namely, the limited capability to quantify recruitment and detect hyperinflation. PEEP-induced recruitment in COVID-19 is heterogeneous and limited in most patients [80]. LUS should be considered as an additional tool, complementary to respiratory mechanics and arterial blood gases, for determining and monitoring the effects of PEEP changes [81].

F) Can LUS guide the use of prone positioning in patients with severe COVID-19?

Statement 11: LUS should be integrated into the assessment of patients considered potential responders to prone positioning, according to the focal and non-focal pattern of lung aeration loss.

Statement 12: LUS can be used to monitor variations in lung aeration during prone positioning.

In conventional ARDS patients, lung ultrasound has been used to monitor the effects of prone positioning on lung reaeration [82, 83]. Haddam et al. showed that ARDS patients with a focal distribution of aeration loss as determined by LUS tended to experience greater reaeration during prone positioning, although it did not correlate with the oxygenation response [84]. In a second study, aeration changes in posterior fields induced by the first 3 h of prone positioning were significantly greater in patients with positive responses and associated with greater levels of oxygenation after 7 days of treatment. Moreover, the lung aeration changes correlated well with the reduction in dead space [85]. Rousset et al. confirm that prone responders present a greater LUS reaeration score at both an early and late stage of prone positioning, corresponding with an increase in endexpiratory lung volume [82]. Similarly, in COVID-19 pneumonia, the improvement in oxygenation following pronation was associated with an improvement in both the global and posterior LUS scores [85]. LUS was proven to be a reliable bedside tool for monitoring lung aeration across the different phases of prone positioning in ARDS patients undergoing invasive mechanical ventilation. Thus, lung aeration monitoring through LUS imaging during pronation could also constitute a valid solution for COVID-19 pneumonia, in which the early prediction of disease progression may prove to be fundamental for the delivery of appropriate healthcare.

G) Can LUS help early diagnosis of pneumothorax in severe COVID-19 patients undergoing invasive mechanical ventilation?

Statement 13: LUS should be used in COVID-19 patients, in line with its clinical appropriateness as ascertained by studies in non-COVID-19 patients.

Analysis of the current literature failed to reveal the presence of studies specifically addressing LUS accuracy in pneumothorax diagnosis in COVID-19 patients. A single observational study by Li et al. [86], involving 42 patients, reported 4 cases of pneumothorax identified by LUS and two cases identified by chest X-ray, but no data on concordance were provided. A multi-center observational study by Zieleskiewicz et al. compared LUS performance against that of CT as the standard reference in the diagnosis of interstitial syndrome, consolidations, pleural effusion, pneumothorax, and pleural irregularity [5]. Unfortunately, no pneumothoraxes were present in 100 case samples; thus, the accuracy of LUS in pneumothorax diagnosis could not be estimated. Consistently, a low incidence of pneumothorax in COVID-19 patients was previously reported by Yang et al. in a single-center observational study of 52 patients [87]. Regarding pneumothorax diagnosis and monitoring, LUS applications in COVID-19 patients must currently rely on non-COVID-19 literature. To date, the role of LUS in pneumothorax diagnosis in the critically ill and in trauma patients is well-recognized [63]. Pneumothorax is defined by the presence of air in the pleural cavity, which, in the majority of cases, collects in the upper part (i.e., in the least dependent part), depending on patient position and habitus. Thus, where air collects, the visceral and parietal layers become separated, and a static pleural line replaces normal lung appearance due to the complete reflection of the US beam by the pleural air. This static pleural line has three features: the absence of lung sliding, the lack of B-lines, and the absence of lung pulse [88–90]. Pneumothorax can be ruled out in 100% of cases if lung sliding and B lines are present [7]. Only one sign is specific enough to rule pneumothorax in the lung-point [91]. This is the ultrasonographic sign that

presents at the pneumothorax border where the visceral and parietal pleural contact each other again. However, lung-point can be challenging to find, or completely absent in very large pneumothorax cases. The accuracy of LUS in pneumothorax diagnosis has been evaluated in many studies, which have been synthesized into four meta-analyses published between 2011 and 2014 [92-95]. The pooled specificity of LUS is reported to vary between 98 and 99%, comparable to chest X-ray, while sensitivity is reported to be between 79 and 91%, far outperforming chest X-ray, the pooled sensitivity of which varies from 40 to 52%. Moreover, LUS has been shown to be a sensitive tool, with a low air volume threshold, able to detect even radio-occult pneumothoraxes (i.e., undetected by chest X-ray), which may inflate further during mechanical ventilation [96, 97]. LUS has also been shown to be a reliable means for semi-quantifying pneumothorax dimension, thus helping in treatment decision-making [98]. In the context of pneumothorax daily reassessment, some controversy exists regarding diagnostic consistency over time, with only one study reporting LUS to be adequately capable of detecting pneumothorax resolution after chest drain clamping and removal [99]. The presence of subcutaneous emphysema, which may accompany cases of pneumomediastinum, may limit this application, complicating mechanical ventilation in some COVID-19 patients [100].

H) Can LUS help the early diagnosis of ventilatorassociated pneumonia in severe COVID-19 patients undergoing invasive mechanical ventilation?

Statement 14: LUS should be used in COVID-19 patients, in line with its clinical appropriateness as ascertained by studies in non-COVID-19 patients.

Ventilator-associated pneumonia (VAP) is the most frequent nosocomial infection occurring in the ICU; it is associated with increased mortality, a greater use of antimicrobials, longer mechanical ventilation, and higher healthcare costs. VAP is suspected in patients under mechanical ventilation presenting fever/hypothermia, leukocytosis/leukopenia, purulent tracheal secretions, and impaired oxygenation [39]. No specific studies have been conducted so far to assess the accuracy of LUS in VAP diagnosis in COVID-19 patients. LUS is well suited to investigate interstitial and subpleural involvement in lung disease, and it is increasingly used in the ICU setting. The extent and severity of lung infiltrates can be described numerically with a reproducible and validated LUS score [39]. More recently, quantitative analysis of the LUS score has been proposed to make the interpretation of findings less operator dependent [6]. VAP-related injuries typically extend from the center to the periphery of the lung; when these lesions reach the subpleural regions, they become identifiable by LUS: a normal A-line pattern with lung sliding is replaced by focal areas of interstitial syndrome, represented by well-spaced B-lines, becoming progressively confluent into subpleural areas of consolidation, where air-bronchograms may be visualized [68]. LUS could become a tool for the detection of VAP in the ICU, but this application has only been investigated so far by three specific studies [6, 39, 68]. The current literature on LUS use in routine practice for COVID-19 patients is encouraging as it seems to accurately reflect disease progression [39]. Specific data on LUS accuracy for the diagnosis of VAP in severe COVID-19 patients undergoing invasive mechanical ventilation are still lacking, and well-designed studies are needed to validate this powerful tool [68].

I) Can LUS help the process of weaning severe COVID-19 patients from invasive mechanical ventilation?

Statement 15: We are unable to create any statement on the use of LUS in the assessment of patient readiness to sustain a spontaneous breathing trial (SBT). No study has evaluated the potential of LUS for this purpose in COVID-19 patients, and data in non-COVID-19 patients are conflicting. Statement 16: In association with standard clinical and physiological indexes, LUS can improve the prediction of SBT outcome in COVID-19 patients.

Statement 17: In association with standard clinical and physiological indexes, LUS can improve the prediction of extubation failure in COVID-19 patients.

The term weaning refers to the whole process leading to the liberation from mechanical ventilation and removal of the endotracheal tube [101]. The process includes a number of steps: (1) assessing spontaneous breathing trial (SBT) readiness; (2) conducting a SBT and assessing its outcome; and (3) predicting extubation failure, which would expose patients to an increased risk of death and prolonged ICU stay [101].

Readiness for SBT is commonly assessed by means of a composite evaluation, including clinical and physiological variables [101]. LUS imaging employed to ascertain patient readiness to undergo an SBT has produced conflicting results in non-COVID-19 patients. In critically ill neurosurgical patients, a high LUS score prior to a 1-h SBT conducted using a T-tube was associated with a higher risk of SBT failure [102]. Conversely, data from a bi-center, prospective, observational investigation, carried out in a heterogeneous population of 250 ready-to-wean patients, showed that B-line predominance prior

to sustaining a T-tube SBT lasting 30–120 min was a very weak predictor of SBT outcome, with 47% sensitivity, 64% specificity, a positive predictive value of 25%, and a negative predictive value of 82% [103]. The authors concluded that the presence of B-lines on a simplified 4-zone LUS protocol should not interfere with the decision to initiate weaning procedures [103].

The outcomes of SBTs and extubation depend on a variety of factors, such as cardiovascular dysfunction, inability of the respiratory muscles to sustain an excessive work of breathing, neuromuscular disorders, severe anemia, altered metabolic, nutritional, or neuropsychological conditions, and the inability to clear secretions [101]. While LUS is not helpful for evaluating some of these factors, it may add to the physician's decisionmaking when associated with clinical and physiological variables and in some cases with cardiac and diaphragm ultrasound assessment [104-106]. In critically ill patients, following the reduction of ventilatory support, the extension of regions affected by aeration loss and pulmonary edema may contribute to weaning failure [105] and can be identified and quantified by LUS [107, 108]. Indeed, variations in LUS patterns reflect changes in pulmonary aeration, which is the final result of different pathways [108–110]. Patients who fail an SBT show lung de-recruitment and inhomogeneity according to electric impedance tomography analysis [111]. In patients invasively ventilated for more than 48 h, a 1-h SBT conducted using a T-tube showed a LUS greater than that observed in patients with successful SBT [104]. These results were subsequently confirmed in a second study conducted in the same setting [109]. In patients intubated for acute respiratory failure of different etiologies undergoing an SBT either in T-tube mode or with 8 cmH₂O of inspiratory pressure support and 5 cmH₂O of positive end-expiratory pressure, the discriminative power of LUS for successful weaning was 0.8 with a sensitivity and specificity of 0.76 and 0.73, respectively [112]. An increase in B-lines to ≥ 6 on four anterior points during a 60-min SBT in T-tube mode was shown to predict weaning-induced pulmonary edema with a sensitivity of 88% (64-98) and a specificity of 88% (62-98) [110]. In elderly patients undergoing an SBT, global and anterolateral LUS predicted failure with a discriminative power of 0.80 and 0.79, respectively [108].

Combining LUS with cardiac and diaphragmatic ultrasound assessment has the potential to improve weaning failure prediction, providing insights into the origin of reduced pulmonary aeration [113, 114]. A modified LUS assessment and diaphragmatic thickening assessment were associated with high predictive accuracy of successful extubation, with an AUC of 0.78 and 0.76, respectively, which increased up to 0.83 when considering both assessments together [112]; however, the relationship

between LUS and diaphragm thickening during an SBT seems to vary according to the degree of pulmonary aeration [115], as well as to the considered subpopulation [116]. LUS in association with the brain natriuretic peptide test, diaphragm dysfunction assessment, and left atrial pressure measurement is a better predictor of weaning failure than LUS alone (AUC 0.91 vs 0.76) [117].

In non-COVID-19 patients, LUS was successfully applied to predict extubation outcome. Regardless of the primary cause of the weaning failure, LUS performed in 100 ICU patients during successful SBTs in T-tube mode was able to predict the occurrence of post-extubation distress [112]. A LUS score higher than 17 was associated with an increased risk of extubation failure, whereas a gray zone was identified for scores ranging from 13 to 17. In patients who successfully passed the SBT with a LUS score > 13, noninvasive ventilation was proposed as a rescue strategy to prevent re-intubation [104]. LUS assessment during successful SBTs with support pressure ventilation <7 cmH2O and no PEEP revealed the occurrence of multiple B-lines as a predictor of post-extubation distress within the first 48 h after extubation [113]. Despite the lack of data in COVID-19 patients, the pathophysiological insights gained from LUS during a SBT to predict extubation failure might be translated to COVID-19 patients. This suggestion arrives from the consideration that observational studies have evaluated the reliability of LUS as a monitoring tool in COVID-19 patients, despite it being a different clinical setting to weaning [42].

Changes in the LUS score during SBTs in COVID-19 patients could add some information concerning the loss of aeration. Cardiac and diaphragm ultrasound assessments might also be able to enhance SBT outcome prediction.

L) Can LUS decrease the need for radiologic chest imaging in severe COVID-19 patients?

Statement 18: In patients with known COVID-19 and severe symptoms, LUS should be performed instead of radiologic chest imaging as the first-line imaging test to monitor disease progression.

Statement 19: LUS findings suggestive of pneumonia can render additional imaging techniques unnecessary, especially when the likelihood of an alternative diagnosis is low.

Statement 20: In COVID-19 patients with severe symptoms, a negative LUS exam should prompt an additional radiologic chest imaging work-up.

Monitoring critically ill patients by serial chest X-ray is not advisable due to the technique's low sensitivity

and long execution time; moreover, it represents a suboptimal allocation of available resources [19].

Conversely, LUS demonstrates high agreement with chest computer tomography (CT), closely mirrors the longitudinal changes found by CT without exposing the personnel to infection risks, and is quick to perform [9]. If integrated into the daily routine examinations, LUS results appear to accurately reflect disease progression, thus reducing the need for chest X-ray and CT [41–118]. Moreover, LUS has been shown capable of monitoring the evolution of severe COVID-19 pneumonia after hospital discharge, supporting its integration into clinical predictive models of residual lung injury, thus providing an alternative imaging modality for the diagnosis and monitoring of critically ill COVID-19 patients [119].

If a patient presents LUS findings suggestive of pneumonia together with a low pre-test probability of an alternative or secondary diagnosis, an additional imaging modality may not be necessary [1–120]; however, a chest CT on admission performs better than LUS for COVID-19 diagnosis, at varying disease prevalence [38], and LUS is highly sensitive but not specific for COVID-19 [121]. Thus, the presence of pre-existing conditions, such as chronic obstructive pulmonary disease or heart failure, and the prevalence of venous thromboembolism in patients with COVID-19 must be taken into account when deciding whether to pursue or not additional chest imaging modalities, which should be individualized on a patient-by-patient basis [120].

In patients with severe symptoms, the probability of entirely normal radiologic findings is low. Thus, in patients with severe symptoms, a negative LUS should prompt additional radiologic chest imaging work-up by chest CT owing to its higher accuracy in imaging centrally based abnormalities and diagnosis of pulmonary embolism [122–124].

Discussion

The panel produced 20 statements in relation to 10 clinical questions on the bedside use of LUS in COVID-19 critically ill patients, summarizing the latest available literature and the direct experience of the expert panelists. As the use of LUS became ineluctable during this pandemic, anesthesiologists and intensive care physicians have been quick to incorporate this important tool into their armamentarium [1, 2, 4–6, 9]. This also reinforces the need to impose training and certification on the use of this tool within our discipline in order to ensure its wider implementation in the near future [125]. Two other groups have proposed consensuses on the use of LUS in the setting of COVID-19 [12, 126]. The Canadian consensus statement on the use of LUS was focused on the assessment of medical inpatients to confirm or rule out the diagnosis of COVID-19 pneumonia [12]. Our consensus not only confirms the use of LUS for COVID-19 pneumonia diagnosis but also details its use as a monitoring tool in the critically ill. A second multi-organ point-of-care ultrasound consensus for COVID-19 patients included a whole-body ultrasound approach [126]. While it supports the use of LUS as an accurate diagnostic tool, the specific use of LUS in routine ICU work was not detailed. Two other society guidelines have been produced: the first by the German societies of clinical acute, emergency, and intensive care medicine and radiology [127] and the second by the British Medical Ultrasound Society (BMUS) [128]. Both are mainly focused on imaging and monitoring techniques in COVID-19, but do not detail the use of LUS in the critically ill. Finally, the European Society of Radiology recently highlighted the role of lung ultrasound in COVID-19 disease in the ICU, supporting its use "to track the evolution of disease during follow-up and to monitor lung recruitment maneuvers, the response to prone position venand the controlling of extracorporeal tilation membrane therapy" [2].

Conclusions

In conclusion, our expert consensus is the first detailing the use of LUS for diagnosis, management, and monitoring of COVID-19 pneumonia in the critically ill patient. We hope that the statements produced will help ICU physicians in their daily clinical practice while facing the ongoing pandemic.

Abbreviations

LUS: Lung ultrasound; COVID-19: Coronavirus disease 2019; SARS-CoV2: Severe acute respiratory syndrome coronavirus 2; ARDS: Acute respiratory distress syndrome; CT: Computed tomography; PEEP: Positive end-expiration pressure; ICU: Intensive care unit; HFNC: High flow nasal cannula; NIV: Non-invasive ventilation; CPAP: Continuous positive airway pressure; PNX: Pneumothorax; VAP: Ventilator-associated pneumonia; SBT: Spontaneous breathing trial; BMUS: British Medical Ultrasound Society

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s44158-021-00015-6.

Additional file 1. Search strategy

Additional file 2: Table S1. PICO question and criteria for inclusion/ exclusion of articles. Fig. S1. PRISMA Flow Diagram. Fig. S2. Report of the first round of voting. For each statement, median score, interquartile range and proportion (percentage) of agreement are reported. Green circle (or red) represents the median score while the horizontal bar represents the interquartile-range. CPAP: Continuous positive airway pressure; COVID-19: Coronavirus diseases 2019; LUS: Lung ultrasound; HFNC: high flow nasal canula; IQR: interquartile range; ICU: Intensive care unit; NIRS: Noninvasive respiratory support; NIV: Noninvasive ventilation; PEEP: Positive end expiratory pressure; RT-PCR: Real-time polymerase chain reaction; SBT: Spontaneous breathing trial

Additional file 3. Full output of the search and the selection of potentially relevant articles

Acknowledgements

The authors would like to thank the Officer, Cristina Cacciagrano, and Executive Officer, Emiliano Tizi, of the Italian Society of Anesthesia, Analgesia, Resuscitation, and Intensive Care (SIAARTI) for their helpful guidance on various technical issues during the preparation and submission of this expert consensus.

Authors' contributions

FM and LV conceived the study idea and coordinated the expert consensus. AC, AI, DP, and DO design the search strategy and examined the correct consensus methodology. PP, PN, EB, TB, and SM were group heads for the assigned clinical questions. Except for the methodologists, the other authors vote for the clinical questions and the statements and wrote the manuscript. All authors read the final version of the manuscript and give final approval. FM and LV contributed equally as co-first authors. All authors agree to be accountable for all aspects of the work. FM and LV were guarantors.

Funding

Samsung (thanks to the unconditional contribution of Samsung)

Availability of data and materials

The data of the present expert consensus is available, on reasonable request, by contacting the corresponding author.

Declarations

Ethic approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Dr. Mojoli F. received a fee for lectures by Hamilton Medical, GE Healthcare, SEDA Spa and consultancy agreement between University of Pavia and Hamilton Medical; Dr. Mongodi S. received fees for lectures by GE healthcare. Dr Vetrugno L. has no conflicts to report; the others authors declare no conflict of interest. Dr. Cortegiani A. has no conflicts to report. Dr. Bignami E. has no conflicts to report. Dr. Ippolito M. has no conflicts to report. Dr Orso D. has no conflicts to report. Dr. Corradi F. has no conflicts to report. Dr Cammarota G. has no conflicts to report. Dr. Boero E. has no conflicts to report. Dr. lacovazzo C. has no conflicts to report. Dr. Vargas M. has no conflicts to report. Dr Poole D has no conflicts to report. Dr Guerino Biasucci D. has no conflicts to report. Dr. Persona P. has no conflicts to report. Dr. Bove T. has no conflicts to report. Dr. Ball L. has no conflicts to report. Dr. Chiumello D. has no conflicts to report. Dr. Forfori F. has no conflicts to report. Dr. De Robertis E. has no conflicts to report. Dr Pelosi P. has no conflicts to report. Dr. Navalesi P. has no conflicts to report. Dr. Giarratano A. has no conflicts to report. Dr. Petrini F. has no conflicts to report.

Author details

¹Department of Medicine, University of Udine, Via Colugna n 50, 33100 Udine, Italy. ²University-Hospital of Friuli Centrale, ASU FC, Udine, Italy. ³Department of Clinical-Surgical, Diagnostic, and Pediatric Sciences, Unit of Anesthesia and Intensive Care, University of Pavia, Pavia, Italy. ⁴Department of Surgical, Oncological and Oral Science (Di.Chir.On.S), University of Palermo, Palermo, Italy. ⁵Department of Anesthesia Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Italy. ⁶Anesthesiology, Critical Care and Pain Medicine Division, Department of Medicine and Surgery, University of Parma, Parma, Italy. ⁷Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy. ⁸Department of Anesthesia and Intensive Care, "Ente Ospedaliero Ospedali Galliera", Genova, Italy. ⁹Department of Medicine and Surgery, University of Perugia, Perugia, Italy. ¹⁰Anesthesia and Intensive Care Unit, San Giovanni Bosco Hospital, Turin, Italy. ¹¹Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy. ¹²Anesthesia and Intensive Care Operative Unit, S. Martino Hospital, Belluno, Italy. ¹³Department of Anesthesia and Intensive Care, Fondazione Policlinico Universitario "A. Gemelli", Rome, Italy. $^{14}\mathrm{UOC}$ Anesthesia and Intensive Care Unit, University Hospital of Padua, Padua, Italy. ¹⁵Department of Surgical Sciences and Integrated Diagnostics (DISC),

University of Genoa, Genoa, Italy. ¹⁶Anesthesia and Critical Care, San Martino Policlinico Hospital, IRCCS for Oncology and Neurosciences, Genoa, Italy. ¹⁷Department of Anesthesia and Intensive Care, ASST Santi Paolo e Carlo, San Paolo University Hospital, Milan, Italy. ¹⁸Italian Society of Anesthesia, Analgesia, Resuscitation, and Intensive Care (SIAARTI), Rome, Italy.

Received: 20 October 2021 Accepted: 25 October 2021 Published online: 24 November 2021

References

- Volpicelli G, Gargani L, Perlini S, Spinelli S, Barbieri G, Lanotte A, Casasola GG, Nogué-Bou R, Lamorte A, Agricola E, Villén T, Deol PS, Nazerian P, Corradi F, Stefanone V, Fraga DN, Navalesi P, Ferre R, Boero E, Martinelli G, Cristoni L, Perani C, Vetrugno L, McDermott C, Miralles-Aguiar F, Secco G, Zattera C, Salinaro F, Grignaschi A, Boccatonda A, Giostra F, Infante MN, Covella M, Ingallina G, Burkert J, Frumento P, Forfori F, Ghiadoni L, on behalf of the International Multicenter Study Group on LUS in COVID-19, Fraccalini T, Vendrame A, Basile V, Cipriano A, Frassi F, Santini M, Falcone M, Menichetti F, Barcella B, Delorenzo M, Resta F, Vezzoni G, Bonzano M, Briganti DF, Cappa G, Zunino I, Demitry L, Vignaroli D, Scattaglia L, di Pietro S, Bazzini M, Capozza V, González MM, Gibal RV, Ibarz RP, Alfaro LM, Alfaro CM, Alins MG, Brown A, Dunlop H, Ralli ML, Persona P, Russel FM, Pang PS, Rovida S, Deana C, Franchini D (2020) on behalf of the International Multicenter Study Group on LUS in COVID-19. Lung ultrasound for the early diagnosis of COVID-19 pneumonia: an international multicenter study. Intensive Care Med 47(4):444-454. https://doi.org/10.1007/s00134-021-063
- European Society of Radiology (ESR) (2021) The role of lung ultrasound in COVID-19 disease. Insights Imaging 12(1):81. https://doi.org/10.1186/s13244-021-01013-6
- Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C (2020) Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 20(4):425–434. https://doi.org/1 0.1016/S1473-3099(20)30086-4
- Gibbons RC, Magee M, Goett H, Murret J, Genninger J, Mendez K, Tripod M et al (2021) Lung ultrasound vs. chest X-ray study for the radiographic diagnosis of COVID-19 pneumonia in a high-prevalence population. J Emerg Med 60(5):615–625. https://doi.org/10.1016/j.jemermed.2021.01.041
- Zieleskiewicz L, Markarian T, Lopez A, Taguet C, Mohammedi N, Boucekine M, Baumstarck K, Besch G, Mathon G, Duclos G, Bouvet L, Michelet P, Allaouchiche B, Chaumoître K, di Bisceglie M, Leone M, on behalf of the AZUREA Network (2020) AZUREA Network. Comparative study of lung ultrasound and chest computed tomography scan in the assessment of severity of confirmed COVID-19 pneumonia. Intensive Care Med 46(9):1707– 1713. https://doi.org/10.1007/s00134-020-06186-0
- Mongodi S, De Luca D, Colombo A, Stella A, Santangelo E, Corradi F et al (2021) Quantitative lung ultrasound: technical aspects and clinical applications. Anesthesiology 134(6):949–965. https://doi.org/10.1097/ALN. 000000000003757
- Volpicelli G (2011) Sonographic diagnosis of pneumothorax. Intensive Care Med 37:224–232. https://doi.org/10.1007/s00134-010-2079-y
- Mongodi S, Via G, Girard M, Rouquette I, Misset B, Braschi A, Mojoli F, Bouhemad B (2016) Lung ultrasound for early diagnosis of ventilatorassociated pneumonia. Chest. 149(4):969–980. https://doi.org/10.1016/j. chest.2015.12.012
- Vetrugno L, Bove T, Orso D, Barbariol F, Bassi F, Boero E, Ferrari G, Kong R (2020) Our Italian experience using lung ultrasound for identification, grading and serial follow-up of severity of lung involvement for management of patients with COVID-19. Echocardiography. 37(4):625–627. https://doi.org/10.1111/echo.14664
- Meroi F, Orso D, Vetrugno L, Bove T (2021) Lung ultrasound score in critically ill COVID-19 patients: a waste of time or a time-saving tool? Acad Radiol 28(9):1323–1324. https://doi.org/10.1016/j.acra.2021.06.008
- Hankins A, Bang H, Walsh P. (2020) Point of care lung ultrasound is useful when screening for COVID-19 in emergency department patients. medRxiv [Preprint]. doi: https://doi.org/10.1101/2020.06.09.20123836.
- 12. Ma IWY, Hussain A, Wagner M, Walker B, Chee A, Arishenkoff S, Buchanan B, Liu RB, Mints G, Wong T, Noble V, Tonelli AC, Dumoulin E, Miller DJ, Hergott CA, Liteplo AS (2021) Canadian Internal Medicine Ultrasound (CIMUS) expert consensus statement on the use of lung ultrasound for the assessment of

- medical inpatients with known or suspected coronavirus disease. J Ultrasound Med 40(9):1879–1892. https://doi.org/10.1002/jum.15571
- Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. (2001)
 The RAND/UCLA appropriateness method user's manual [internet]. Available from: http://www.rand.org/pubs/monograph_reports/MR1269.html.
- Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM et al (2014) Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 67:401–409. https:// doi.org/10.1016/j.jclinepi.2013.12.002
- Laursen CB, Sloth E, Lassen AT, Rd C, Lambrechtsen J, Madsen PH et al (2014) Point-of-care ultrasonography in patients admitted with respiratory symptoms: a single-blind, randomised controlled trial. Lancet Respir Med 2(8):638–646. https://doi.org/10.1016/S2213-2600(14)70135-3
- Pivetta E, Goffi A, Lupia E, Tizzani M, porrino G, Ferreri E, et al. (2015) SIMEU Group for lung ultrasound in the emergency department in piedmont. Lung ultrasound-implemented diagnosis of acute decompensated heart failure in the ED: a SIMEU multicenter study. Chest. 148(1):202–210. https://doi.org/10.1378/chest.14-2608
- Tan G, Lian X, Zhu Z, Wang Z, Huang F, Zhang Y, Zhao Y, He S, Wang X, Shen H, Lyu G (2020) Use of lung ultrasound to differentiate coronavirus disease 2019 (COVID-19) pneumonia from community-acquired pneumonia. Ultrasound Med Biol 46(10):2651–2658. https://doi.org/10.1016/j.ultra smedbio.2020.05.006
- Vezzani A, Manca T, Brusasco C, Santori G, Valentino M, Nicolini F, Molardi A, Gherli T, Corradi F (2014) Diagnostic value of chest ultrasound after cardiac surgery: a comparison with chest X-ray and auscultation. J Cardiothorac Vasc Anesth 28(6):1527–1532. https://doi.org/10.1053/j.jvca.2014.04.012
- Tierney DM, Huelster JS, Overgaard JD, Plunkett MB, Boland LL, St Hill CA et al (2020) Comparative performance of pulmonary ultrasound, chest radiograph, and CT among patients with acute respiratory failure. Crit Care Med 48(2):151–157. https://doi.org/10.1097/CCM.0000000000004124
- Corradi F, Ball L, Brusasco C, Riccio AM, Baroffio M, Bovio G, Pelosi P, Brusasco V (2013) Assessment of extravascular lung water by quantitative ultrasound and CT in isolated bovine lung. Respir Physiol Neurobiol 187(3): 244–249. https://doi.org/10.1016/j.resp.2013.04.002
- Ye X, Xiao H, Chen B, Zhang S (2015) Accuracy of lung ultrasonography versus chest radiography for the diagnosis of adult community-acquired pneumonia: review of the literature and meta-analysis. PLoS One 10(6): e0130066. https://doi.org/10.1371/journal.pone.0130066
- Pare JR, Camelo I, Mayo KC, Leo MM, Dugas JN, Nelson KP, Baker W, Shareef F, Mitchell P, Schechter-Perkins E (2020) Point-of-care lung ultrasound is more sensitive than chest radiograph for evaluation of COVID-19. West J Emerg Med 21(4):771–778. https://doi.org/10.5811/westjem.2020.5.47743
- Llamas-Álvarez AM, Tenza-Lozano EM, Latour-Pérez J (2017) Accuracy of lung ultrasonography in the diagnosis of pneumonia in adults: systematic review and meta-analysis. Chest. 151(2):374–382. https://doi.org/10.1016/j. chest.2016.10.039
- Volpicelli G, Lamorte A, Villén T (2020) What's new in lung ultrasound during the COVID-19 pandemic. Intensive Care Med 46(7):1445–1448. https://doi.org/10.1007/s00134-020-06048-9
- Kirkpatrick AW, McKee JL (2021) Re: "Proposal for international standardization of the use of lung ultrasound for patients with COVID-19: a simple, quantitative, reproducible method"- could telementoring of lung ultrasound reduce health care provider risks, especially for paucisymptomatic home-isolating patients? J Ultrasound Med 40(1):211– 212. https://doi.org/10.1002/jum.15390
- Poggiali E, Dacrema A, Bastoni D, Tinelli V, Demichele E, Mateo Ramos P, Marcianò T, Silva M, Vercelli A, Magnacavallo A (2020) Can lung US help critical care clinicians in the early diagnosis of novel coronavirus (COVID-19) pneumonia? Radiology 295(3):E6. https://doi.org/10.1148/radiol.2020200847
- Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, Ji W (2020) Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology 296(2):E115–E117. https://doi.org/10.1148/radiol.2020200432
- Schultz MJ, Sivakorn C, Dondorp AM (2020) Challenges and opportunities for lung ultrasound in novel coronavirus disease (COVID-19). Am J Trop Med Hyg 102(6):1162–1163. https://doi.org/10.4269/ajtmh.20-0323
- Peyrony O, Marbeuf-Gueye C, Truong V, Giroud M, Rivière C, Khenissi K, Legay L, Simonetta M, Elezi A, Principe A, Taboulet P, Ogereau C, Tourdjman M, Ellouze S, Fontaine JP (2020) Accuracy of emergency department clinical findings for diagnosis of coronavirus disease 2019. Ann Emerg Med 76(4): 405–412. https://doi.org/10.1016/j.annemergmed.2020.05.022

- Tung-Chen Y, Algora-Martín A, Llamas-Fuentes R, Rodriguez-Fuertes P, Martinez Virto AM, Sanz-Rodriguez E et al (2021) Point-of-care ultrasonography in the initial characterization of patients with COVID-19. Med Clin (Barc) 156(10):477–484. https://doi.org/10.1016/j.medcli.2020.12.007
- Mohamed MFH, Al-Shokri S, Yousaf Z, Danjuma M, Parambil J, Mohamed S et al (2020) Frequency of abnormalities detected by point-of-care lung ultrasound in symptomatic COVID-19 patients: systematic review and meta-analysis. Am J Trop Med Hyg 103(2):815–821. https://doi.org/10.4269/ajtmh.20-0371
- 32. Vetrugno L, Baciarello M, Bignami E, Bonetti A, Saturno F, Orso D, Girometti R, Cereser L, Bove T (2020) The "pandemic" increase in lung ultrasound use in response to COVID-19: can we complement computed tomography findings? A narrative review. Ultrasound J 12(1):39. https://doi.org/10.1186/s13089-020-00185-4
- Kalafat E, Yaprak E, Cinar G, Varli B, Ozisik S, Uzun C, Azap A, Koc A (2020) Lung ultrasound and computed tomographic findings in pregnant woman with COVID-19. Ultrasound Obstet Gynecol 55(6):835–837. https://doi.org/1 0.1002/uoq.22034
- Bonadia N, Carnicelli A, Piano A, Buonsenso D, Gilardi E, Kadhim C, Torelli E, Petrucci M, di Maurizio L, Biasucci DG, Fuorlo M, Forte E, Zaccaria R, Franceschi F (2020) Lung ultrasound findings are associated with mortality and need for intensive care admission in COVID-19 patients evaluated in the emergency department. Ultrasound Med Biol 46(11):2927–2937. https:// doi.org/10.1016/j.ultrasmedbio.2020.07.005
- Bosso G, Allegorico E, Pagano A, Porta G, Serra C, Minerva V, Mercurio V, Russo T, Altruda C, Arbo P, de Sio C, dello Vicario F, Numis FG (2021) Lung ultrasound as diagnostic tool for SARS-CoV-2 infection. Intern Emerg Med 16(2):471–476. https://doi.org/10.1007/s11739-020-02512-y
- Brahier T, Meuwly JY, Pantet O, Brochu Vez MJ, Gerhard Donnet H, Hartley MA, Hugli O, Boillat-Blanco N (2020) Lung ultrasonography for risk stratification in patients with COVID-19: a prospective observational cohort study. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa1408
- Castelao J, Graziani D, Soriano JB, Izquierdo JL (2021) Findings and prognostic value of lung ultrasound in COVID-19 pneumonia. J Ultrasound Med 40(7):1315–1324. https://doi.org/10.1002/jum.15508
- Colombi D, Petrini M, Maffi G, Villani GD, Bodini FC, Morelli N, Milanese G, Silva M, Sverzellati N, Michieletti E (2020) Comparison of admission chest computed tomography and lung ultrasound performance for diagnosis of COVID-19 pneumonia in populations with different disease prevalence. Eur J Radiol 133:109344. https://doi.org/10.1016/j.ejrad.2020.109344
- Dargent A, Chatelain E, Kreitmann L, Quenot JP, Cour M, Argaud L (2020) Lung ultrasound score to monitor COVID-19 pneumonia progression in patients with ARDS.; COVID-LUS study group. PLoS One 15(7):e0236312. https://doi.org/10.1371/journal.pone.0236312
- de Alencar JCG, Marchini JFM, Marino LO, da Costa Ribeiro SC, Bueno GG, da Cunha VP et al (2021) Lung ultrasound score predicts outcomes in COVID-19 patients admitted to the emergency department. Ann Intensive Care 11(1):6. https://doi.org/10.1186/s13613-020-00799-w
- Deng Q, Zhang Y, Wang H, Chen L, Yang Z, Peng Z, Liu Y, Feng C, Huang X, Jiang N, Wang Y, Guo J, Sun B, Zhou Q (2020) Semiquantitative lung ultrasound scores in the evaluation and follow-up of critically ill patients with COVID-19: a single-center study. Acad Radiol 27(10):1363–1372. https:// doi.org/10.1016/j.acra.2020.07.002
- Ji L, Cao C, Gao Y, Zhang W, Xie Y, Duan Y, Kong S, You M, Ma R, Jiang L, Liu J, Sun Z, Zhang Z, Wang J, Yang Y, Lv Q, Zhang L, Li Y, Zhang J, Xie M (2020) Prognostic value of bedside lung ultrasound score in patients with COVID-19. Crit Care 24(1):700. https://doi.org/10.1186/s13054-020-03416-1
- Lichter Y, Topilsky Y, Taieb P, Banai A, Hochstadt A, Merdler I, Gal Oz A, Vine J, Goren O, Cohen B, Sapir O, Granot Y, Mann T, Friedman S, Angel Y, Adi N, Laufer-Perl M, Ingbir M, Arbel Y, Matot I, Szekely Y (2020) Lung ultrasound predicts clinical course and outcomes in COVID-19 patients. Intensive Care Med 46(10):1873–1883. https://doi.org/10.1007/s00134-020-06212-1
- Mento F, Perrone T, Narvena Macioce V, Tursi F, Buonsenso D, Torri E et al (2020) On the impact of different lung ultrasound imaging protocols in the evaluation of patients affected by coronavirus disease 2019: how many acquisitions are needed? J Ultrasound Med 40(10):2235–2238. https://doi. org/10.1002/jum.15580
- 45. Perrone T, Soldati G, Padovini L, Fiengo A, Lettieri G, Sabatini U, Gori G, Lepore F, Garolfi M, Palumbo I, Inchingolo R, Smargiassi A, Demi L, Mossolani EE, Tursi F, Klersy C, di Sabatino A (2021) A new lung ultrasound protocol able to predict worsening in patients affected by severe acute

- respiratory syndrome coronavirus 2 pneumonia. J Ultrasound Med 40(8): 1627–1635. https://doi.org/10.1002/jum.15548
- Rojatti M, Regli IB, Zanforlin A, Ferretti E, Falk M, Strapazzon G, Gamper M, Zanon P, Bock M, Rauch S (2020) Lung ultrasound and respiratory pathophysiology in mechanically ventilated COVID-19 patients an observational trial. SN Compr Clin Med:1–8. https://doi.org/10.1007/s42399-020-00536-1
- Sahu AK, Mathew R, Bhoi S, Sinha TP, Nayer J, Aggarwal P et al (2021) Lung sonographic findings in COVID-19 patients. Am J Emerg Med 45:324–328. https://doi.org/10.1016/j.ajem.2020.08.080
- Zhao L, Yu K, Zhao Q, Tian R, Xie H, Xie L, Deng P, Xie G, Bao A, du J (2020) Lung ultrasound score in evaluating the severity of coronavirus disease 2019 (COVID-19) pneumonia. Ultrasound Med Biol 46(11):2938–2944. https://doi.org/10.1016/j.ultrasmedbio.2020.07.024
- Zhu ST, Tao FY, Xu JH, Liao SS, shen CL, Liang ZH, et al. (2021) Utility of point-of-care lung ultrasound for clinical classification of COVID-19. Ultrasound Med Biol 47(2):214–221. https://doi.org/10.1016/j.ultrasmedbio.2 020.09.010
- Zhu F, Zhao X, Wang T, Guo F, Xue H, Chang P et al (2021) Ultrasonic characteristics and severity assessment of lung ultrasound in COVID-19 pneumonia in Wuhan, China: a retrospective, observational study. Eng (Beijing) 7:367–375. https://doi.org/10.1016/j.eng.2020.09.007
- Wangüemert Pérez AL, Figueira Gonçalves JM, Hernández Pérez JM, Ramallo Fariña Y, Del Castillo Rodriguez JC (2021) Prognostic value of lung ultrasound and its link with inflammatory biomarkers in patients with SARS-CoV-2 infection. Respir Med Res 79:100809. https://doi.org/10.1016/j.resmer.2 020.100809
- Veronese N, Sbrogiò LG, Valle R, Marin L, Boscolo Fiore E, Tiozzo A (2020) Prognostic value of lung ultrasonography in older nursing home residents affected by COVID-19. J Am Med Dir Assoc 21(10):1384–1386. https://doi. org/10.1016/j.jamda.2020.07.034
- Recinella G, Marasco G, Tufoni M, Brizi M, Evangelisti E, Maestri L, Fusconi M, Calogero P, Magalotti D, Zoli M (2021) Clinical role of lung ultrasound for the diagnosis and prognosis of coronavirus disease pneumonia in elderly patients: a pivotal study. Gerontology 67(1):78–86. https://doi.org/10.1159/ 000512209
- Biasucci DG, Buonsenso D, Piano A, Bonadia N, Vargas J, Settanni D, et al. (2021) Lung ultrasound predicts non-invasive ventilation outcome in COVID-19 acute respiratory failure: a pilot study. Minerva Anestesiol. doi: 10. 23736/S0375-9393.21.15188-0.
- Smargiassi A, Soldati G, Torri E, Mento F, Milardi D, Del Giacomo P et al (2021) Lung ultrasound for COVID-19 patchy pneumonia: extended or limited evaluations? J Ultrasound Med 40(3):521–528. https://doi.org/10.1 002/jum.15428
- Seiler C, Klingberg C, Hårdstedt M (2021) Lung Ultrasound for identification of patients requiring invasive mechanical ventilation in COVID-19. J Ultrasound Med 40(11):2339–2351. https://doi.org/10.1002/jum.15617
- Magnani E, Mattei L, Paolucci E, Magalotti G, Giacalone N, Praticò C, Praticò B, Zani MC (2020) Lung ultrasound in severe COVID-19 pneumonia in the sub-intensive care unit: beyond the diagnostic purpose. Respir Med Case Rep 31:101307. https://doi.org/10.1016/j.rmcr.2020.101307
- Mongodi S, Santangelo E, Salve G, Pregnolato S, Bonaiti S, Stella A et al (2019) Lung ultrasound score to monitor non-invasive respiratory support in hypoxemic patients. Eur Respir J 54:PA2322. https://doi.org/10.1183/13993 003.congress-2019.PA2322
- Bouhemad B, Brisson H, Le-Guen M, Arbelot C, Lu Q, Rouby JJ (2011)
 Bedside ultrasound assessment of positive end-expiratory pressure-induced lung recruitment. Am J Respir Crit Care Med 183(3):341–347. https://doi. org/10.1097/CCM.000000000003340
- Mojoli F, Bouhemad B, Mongodi S, Lichtenstein D (2019) Lung ultrasound for critically ill patients. Am J Respir Crit Care Med 199(6):701–714. https://doi.org/10.1164/rccm.201802-0236CI
- López Vega JM, Parra Gordo ML, Diez Tascón A, Ossaba Vélez S. (2020) Pneumomediastinum and spontaneous pneumothorax as an extrapulmonary complication of COVID-19 disease. Emerg Radiol. 27:727-730 doi.org/10.1007/s10140-020-01806-0.
- 62. Nalewajska M, Feret W, Wojczyński Ł, Witkiewicz W, Wisniewska M, Kotfis K (2021) Spontaneous pneumothorax in COVID-19 patients treated with high-flow nasal cannula outside the ICU: a case series. Int J Environ Res Public Health 18(4):2191. https://doi.org/10.3390/ijerph18042191

- Volpicelli G, Elbarbary M, Blaivas M, Lichtenstein DA, Mathis G, Kirkpatrick AW, International liaison committee on lung ultrasound (ILC-LUS) for international consensus conference on lung ultrasound (ICC-LUS) et al (2012) International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med 38(4):577–591. https://doi.org/10.1007/ s00134-012-2513-4
- Soldati G, Testa A, Pignataro G, Portale G, Biasucci DG, Leone A, Silveri NG (2006) The ultrasonographic deep sulcus sign in traumatic pneumothorax. Ultrasound Med Biol 32(8):1157–1163. https://doi.org/10.1016/j.ultrasmedbio.2006.04.006
- NG L, Saul T, Lewiss RE. (2013) Sonographic evidence of spontaneous pneumomediastinum. Am J Emerg Med 31:462.e3–462.e4. https://doi.org/1 0.1016/j.ajem.2012.08.019
- Testa A, Candelli M, Pignataro G, Costantini AM, Pirronti T, Silveri NG (2008) Sonographic detection of spontaneous pneumomediastinum. J Ultrasound Med 27(10):1508–1509. https://doi.org/10.7863/jum.2008.27.10.1507
- Bouhemad B, Mongodi S, Via G, Rouquette I (2015) Ultrasound for "lung monitoring" of ventilated patients. Anesthesiology 122(2):437–447. https://doi.org/10.1097/ALN.0000000000000558
- Pradhan S, Shrestha PS, Shrestha GS, Marhatta MN (2020) Clinical impact of lung ultrasound monitoring for diagnosis of ventilator associated pneumonia: a diagnostic randomized controlled trial. J Crit Care 58:65–71. https://doi.org/10.1016/j.jcrc.2020.03.012
- Chiumello D, Mongodi S, Algieri I, Vergieri GL, Orlando A, Via G et al (2018)
 Assessment of lung aeration and recruitment by CT scan and ultrasound in acute respiratory distress syndrome patients. Crit Care Med 46(11):1761–1768. https://doi.org/10.1097/CCM.000000000003340
- Bouhemad B, Liu ZH, Arbelot C, Zhang M, Ferrari F, Le-Guen M et al (2010) Ultrasound assessment of antibiotic-induced pulmonary reaeration in ventilator-associated pneumonia. Crit Care Med 38(1):84–92. https://doi. org/10.1097/CCM.0b013e3181b08cdb
- 71. Mongodi S, Pozzi M, Orlando A, Bouhemad B, Stella A, Tavazzi G, Via G, lotti GA, Mojoli F (2018) Lung ultrasound for daily monitoring of ARDS patients on extracorporeal membrane oxygenation: preliminary experience. Intensive Care Med 44(1):123–124. https://doi.org/10.1007/s00134-017-4941-7
- Mongodi S, Colombo A, Orlando A, Cavagna L, Bouhemad B, Lotti GA et al (2020) Combined ultrasound-CT approach to monitor acute exacerbation of interstitial lung disease. Ultrasound J 12(1):27. https://doi.org/10.1186/s13 089-020-00174-7
- Caltabeloti F, Monsel A, Arbelot C, Brisson H, Lu Q, Gu WJ et al (2014) Early fluid loading in acute respiratory distress syndrome with septic shock deteriorates lung aeration without impairing arterial oxygenation: a lung ultrasound observational study. Crit Care 18(3):R91. https://doi.org/10.1186/ cc13859
- 74. Torino C, Gargani L, Sicari R, Letachowicz K, Ekart R, Fliser D, Covic A, Siamopoulos K, Stavroulopoulos A, Massy ZA, Fiaccadori E, Caiazza A, Bachelet T, Slotki I, Martinez-Castelao A, Coudert-Krier MJ, Rossignol P, Gueler F, Hannedouche T, Panichi V, Wiecek A, Pontoriero G, Sarafidis P, Klinger M, Hojs R, Seiler-Mussler S, Lizzi F, Siriopol D, Balafa O, Shavit L, Tripepi R, Mallamaci F, Tripepi G, Picano E, London GM, Zoccali C (2016) The agreement between auscultation and lung ultrasound in hemodialysis patients: the LUST Study. Clin J Am Soc Nephrol 11(11):2005–2011. https://doi.org/10.2215/CJN.03890416
- Lichtenstein D, Mezière G, Seitz J (2009) The dynamic air bronchogram. A lung ultrasound sign of alveolar consolidation ruling out atelectasis. Chest. 135(6):1421–1425. https://doi.org/10.1378/chest.08-2281
- Mojoli F, Bouhemad B, Volpicelli G, Mongodi S (2020) Lung ultrasound modifications induced by fibreoptic bronchoscopy may improve early bedside ventilator-associated pneumonia diagnosis: a case series. Eur J Anaesthesiol 37(10):946–949. https://doi.org/10.1097/EJA.0000000000001254
- de Almeida Monteiro RA, Duarte-Neto AN, Ferraz da Silva LF, de Oliveira EP, do ECT N, Mauad T et al (2021) Ultrasound assessment of pulmonary fibroproliferative changes in severe COVID-19: a quantitative correlation study with histopathological findings. Intensive Care Med 47(2):199–207. https://doi.org/10.1007/s00134-020-06328-4
- Haaksma ME, Heldeweg MLA, Lopez Matta JE, Smit JM, van Trigt JD, Nooitgedacht JS et al (2020) Lung ultrasound findings in patients with novel SARS-CoV-2. ERJ Open Res 6(4):00238–02020. https://doi.org/10.11 83/23120541.00238-2020
- Zotzmann V, Lang CN, Wengenmayer T, Bemtgen X, Schmid B, Muller-Peltzer K et al (2021) Combining lung ultrasound and wells score for

- diagnosing pulmonary embolism in critically ill COVID-19 patients. J Thromb Thrombolysis 52(1):76–84. https://doi.org/10.1007/s11239-020-02323-0
- Mauri T, Spinelli E, Scotti E, Colussi G, basile MC, Crotti S, et al. (2020) Potential for lung recruitment and ventilation-perfusion mismatch in patients with the acute respiratory distress syndrome from coronavirus disease 2019. Crit Care Med 48(8):1129–1134. https://doi.org/10.1097/CCM. 0000000000004386
- 81. Ball L, Robba C, Maiello L, Herrmann J, Gerard SE, Xin Y et al (2021) GECOVID (GEnoa COVID-19) group. Computed tomography assessment of PEEP-induced alveolar recruitment in patients with severe COVID-19 pneumonia. Crit Care 25(1):81. https://doi.org/10.1186/s13054-021-03477-w
- Rousset D, Sarton B, Riu B, Bataille B, Silva S, of the PLUS study group (2021)
 Bedside ultrasound monitoring of prone position induced lung inflation.
 Intensive Care Med 47(5):626–628. https://doi.org/10.1007/s00134-021-06347-9
- Wang XT, Ding X, Zhang HM, Chen H, Su LX, Liu DW et al (2016) Chinese Critical Ultrasound Study Group (CCUSG). Lung ultrasound can be used to predict the potential of prone positioning and assess prognosis in patients with acute respiratory distress syndrome. Crit Care 20:385. https://doi.org/1 0.1186/s13054-016-1558-0
- Haddam M, Zieleskiewicz L, Perbet S, Baldovini A, Guervilly C, Arbelot C, CAR'Echo Collaborative Network, AzuRea Collaborative Network et al (2016) Lung ultrasonography for assessment of oxygenation response to prone position ventilation in ARDS. Intensive Care Med 42(10):1546–1556. https://doi.org/10.1007/s00134-016-4411-7
- Avdeev SN, Nekludova GV, Trushenko NV, Tsareva NA, Yaroshetskiy AI, Kosanovic D et al (2021) Lung ultrasound can predict response to the prone position in awake non-intubated patients with COVID-19 associated acute respiratory distress syndrome. Crit Care 25(1):35. https://doi.org/10.11 86/s13054-021-03472-1
- Li R, Liu H, Qi H, Yuan Y, Zou X, Huang H, Wan J, Lv Z, Ouyang Y, Pan S, Zhao X, Shu H, Shang Y (2021) Lung ultrasound assessment of acute respiratory distress syndrome caused by coronavirus disease 2019: an observational study. Hong Kong J Emerg Med 28(1):8–14. https://doi.org/1 0.1177/1024907920969326
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H et al (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 8(5):475–481. https://doi.org/10.1016/S2213-2600(20)30079-5
- Lichtenstein DA, Menu Y (1995) A bedside ultrasound sign ruling out pneumothorax in the critically ill. Lung sliding. Chest 108(5):1345–1348. https://doi.org/10.1378/chest.108.5.1345
- 89. Lichtenstein D, Mezière G, Biderman P, Gepner A (1999) The comet-tail artifact: an ultrasound sign ruling out pneumothorax. Intensive Care Med 25(4):383–388. https://doi.org/10.1007/s001340050862
- Lichtenstein DA, Lascols N, Prin S, Mezière G (2003) The "lung pulse": an early ultrasound sign of complete atelectasis. Intensive Care Med 29(12): 2187–2192. https://doi.org/10.1007/s00134-003-1930-9
- 91. Lichtenstein D, Mezière G, Biderman P, Gepner A (2000) The "lung point": an ultrasound sign specific to pneumothorax. Intensive Care Med 26(10):1434–1440. https://doi.org/10.1007/s001340000627
- Ding W, Shen Y, Yang J, He X, Zhang M (2011) Diagnosis of pneumothorax by radiography and ultrasonography: a meta-analysis. Chest. 140(4):859–866. https://doi.org/10.1378/chest.10-2946
- Alrajhi K, Woo MY, Vaillancourt C (2012) Test characteristics of ultrasonography for the detection of pneumothorax: a systematic review and meta-analysis. Chest. 141(3):703–708. https://doi.org/10.1378/chest.11-0131
- Alrajab S, Youssef AM, Akkus NI, Caldito G (2013) Pleural ultrasonography versus chest radiography for the diagnosis of pneumothorax: review of the literature and meta-analysis. Crit Care 17(5):R208. https://doi.org/10.1186/ cc13016
- 95. Ebrahimi A, Yousefifard M, Mohammad Kazemi H, Rasouli HR, Asady H, Moghadas Jafari A, Hosseini M (2014) Diagnostic accuracy of chest ultrasonography versus chest radiography for identification of pneumothorax: a systematic review and meta-analysis. Tanaffos 13(4):29–40
- Oveland NP, Søreide E, Lossius HM, Johannessen F, Wemmelund KB, Aagaard R, Sloth E (2013) The intrapleural volume threshold for ultrasound detection of pneumothoraces: an experimental study on porcine models. Scand J Trauma Resusc Emerg Med 21(1):11. https://doi.org/10.1186/1757-7241-21-11
- 97. Oveland NP, Lossius HM, Wemmelund K, Stokkeland PJ, Knudsen L, Sloth E (2013) Using thoracic ultrasonography to accurately assess pneumothorax

- progression during positive pressure ventilation: a comparison with CT scanning. Chest. 143(2):415–422. https://doi.org/10.1378/chest.12-1445
- Volpicelli G, Boero E, Sverzellati N, Cardinale L, Busso M, Boccuzzi F et al (2014) Semi-quantification of pneumothorax volume by lung ultrasound. Intensive Care Med 40(10):1460–1467. https://doi.org/10.1007/s00134-014-3402-9
- Galbois A, Ait-Oufella H, Baudel JL, Kofman T, Bottero J, Viennot S, Rabate C, Jabbouri S, Bouzeman A, Guidet B, Offenstadt G, Maury E (2010) Pleural ultrasound compared with chest radiographic detection of pneumothorax resolution after drainage. Chest. 138(3):648–655. https://doi.org/10.1378/ chest.09-2224
- Belletti A, Palumbo D, Zangrillo A, Fominskly EV, Franchini S, Dell'Acqua A, et al. (2021) COVID-BioB Study Group. Predictors of pneumothorax/ pneumomediastinum in mechanically ventilated COVID-19 patients. J Cardiothorac Vasc Anesth. doi: https://doi.org/10.1053/j.jvca.2021.02.008.
- Boles JM, Bion J, Connors A, Herridge M, Marsh B, Melot C, Pearl R, Silverman H, Stanchina M, Vieillard-Baron A, Welte T (2007) Weaning from mechanical ventilation. Eur Respir J 29(5):1033–1056. https://doi.org/10.11 83/09031936.00010206
- 102. Sachin S, Chakrabarti D, Gopalakrishna KN, Bharadwaj S (2021) Ultrasonographic evaluation of lung and heart in predicting successful weaning in mechanically ventilated neurosurgical patients. J Clin Monit Comput 35(1):189–197. https://doi.org/10.1007/s10877-020-00460-8
- Antonio ACP, Knorst MM, Teixeira C (2018) Lung ultrasound prior to spontaneous breathing trial is not helpful in the decision to wean. Respir Care 63(7):873–878. https://doi.org/10.4187/respcare.05817
- 104. Soummer A, Perbet S, Brisson H, Arbelot C, Constantin JM, Lu Q, Rouby JJ, Lung Ultrasound Study Group (2012) Lung ultrasound study group. Ultrasound assessment of lung aeration loss during a successful weaning trial predicts postextubation distress*. Crit Care Med 40(7):2064–2072. https://doi.org/10.1097/CCM.0b013e31824e68ae
- 105. Tuinman PR, Jonkman AH, Dres M, Shi ZH, Goligher EC, Goffi A, de Korte C, Demoule A, Heunks L (2020) Respiratory muscle ultrasonography: methodology, basic and advanced principles and clinical applications in ICU and ED patients-a narrative review. Intensive Care Med 46(4):594–605. https://doi.org/10.1007/s00134-019-05892-8
- Papanikolaou J, Makris D, Saranteas T, Karakitsos D, Zintzaras E, Karabinis A, Kostopanagiotou G, Zakynthinos E (2011) New insights into weaning from mechanical ventilation: left ventricular diastolic dysfunction is a key player. Intensive Care Med 37(12):1976–1985. https://doi.org/10.1007/s00134-011-2368-0
- 107. Bruni A, Garofalo E, Pasin L, Serraino GF, Cammarota G, Longhini F, Landoni G, Lembo R, Mastroroberto P, Navalesi P (2020) MaGIC (Magna Graecia Intensive care and Cardiac surgery) Group. Diaphragmatic dysfunction after elective cardiac surgery: a prospective observational study. J Cardiothorac Vasc Anesth 34(12):3336–3344. https://doi.org/10.1053/i.jvca.2020.06.038
- 108. Bouhemad B, Mojoli F, Nowobilski N, Hussain A, Rouquette I, Guinot PG, Mongodi S (2020) Use of combined cardiac and lung ultrasound to predict weaning failure in elderly, high-risk cardiac patients: a pilot study. Intensive Care Med 46(3):475–484. https://doi.org/10.1007/s00134-019-05902-9
- 109. Jabaudon M, Perbet S, Pereira B, Soummer A, Roszyk L, Guérin R, Futier E, Lu Q, Bazin JE, Sapin V, Rouby JJ, Constantin JM (2013) Plasma levels of sRAGE, loss of aeration and weaning failure in ICU patients: a prospective observational multicenter study. PLoS One 8(5):e64083. https://doi.org/10.1371/journal.pone.0064083
- 110. Ferré A, Guillot M, Lichtenstein D, Mezière G, Richard C, Teboul JL, Monnet X (2019) Lung ultrasound allows the diagnosis of weaning-induced pulmonary oedema. Intensive Care Med 45(5):601–608. https://doi.org/10.1007/s00134-019-05573-6
- 111. Longhini F, Maugeri J, Andreoni C, Ronco C, Bruni A, Garofalo E, Pelaia C, Cavicchi C, Pintaudi S, Navalesi P (2019) Electrical impedance tomography during spontaneous breathing trials and after extubation in critically ill patients at high risk for extubation failure: a multicenter observational study. Ann Intensive Care 9(1):88. https://doi.org/10.1186/s13613-019-0565-0
- 112. Tenza-Lozano E, Llamas-Alvarez A, Jaimez-Navarro E, Fernàndez-Sànchez J (2018) Lung and diaphragm ultrasound as predictors of success in weaning from mechanical ventilation. Crit Ultrasound J 10(1):12. https://doi.org/10.11 86/s13089-018-0094-3
- 113. Silva S, Ait Aissa D, Cocquet P, Hoarau L, Ruiz J, Ferre F, Rousset D, Mora M, Mari A, Fourcade O, Riu B, Jaber S, Bataille B (2017) Combined thoracic ultrasound assessment during a successful weaning trial predicts postextubation distress. Anesthesiology 127(4):666–674. https://doi.org/10.1097/ALN.000000000001773

- 114. Vetrugno L, Brussa A, Guadagnin GM, Orso D, De Lorenzo F, Cammarota G et al (2020) Mechanical ventilation weaning issues can be counted on the fingers of just one hand: part 2. Ultrasound J 12(1):15. https://doi.org/10.11 86/s13089-020-00160-z
- 115. Xia J, Qian CY, Yang L, Li MJ, Liu XX, Yang T, Lu Q (2019) Influence of lung aeration on diaphragmatic contractility during a spontaneous breathing trial: an ultrasound study. J Intensive Care 7(1):54. https://doi.org/10.1186/s4 0560-019-0409-x
- 116. Cammarota G, Rossi E, Vitali L, Simonte R, Sannipoli T, Anniciello F et al (2021) Effect of awake prone position on diaphragmatic thickening fraction in patients assisted by noninvasive ventilation for hypoxemic acute respiratory failure related to novel coronavirus disease. Crit Care 25(1):305 doi.org/10.1186/s13054-021-03735-x
- 117. Xu X, Wu R, Zhang YJ, Li HW, He XH, Wang SM (2020) Value of combination of heart, lung, and diaphragm ultrasound in predicting weaning outcome of mechanical ventilation. Med Sci Monit 26:e924885. https://doi.org/10.12
- 118. Mongodi S, Orlando A, Arisi E, Tavazzi G, Santangelo E, Caneva L, Pozzi M, Pariani E, Bettini G, Maggio G, Perlini S, Preda L, lotti GA, Mojoli F (2020) Lung ultrasound in patients with acute respiratory failure reduces conventional imaging and health care provider exposure to COVID-19. Ultrasound Med Biol 46(8):2090–2093. https://doi.org/10.1016/j.ultrasmedbio.2020.04.033
- 119. Alharthy A, Abuhamdah M, Balhamar A, Faqihi F, Nasim N, Ahmad S, Noor A, Tamim H, Alqahtani SA, Abdulaziz al Saud AAASB, Kutsogiannis DJ, Brindley PG, Memish ZA, Karakitsos D, Blaivas M (2021) Residual lung injury in patients recovering from COVID-19 critical illness: a prospective longitudinal point-of-Care lung ultrasound study. J Ultrasound Med 40(9): 1823–1838. https://doi.org/10.1002/jum.15563
- 120. Volpicelli G, Gargani L (2020) Sonographic signs and patterns of COVID-19 pneumonia. Ultrasound J 12(1):22. https://doi.org/10.1186/s13089-020-00171-w
- 121. Vetrugno L, Bove T, Orso D, Bassi F, Boero E, Ferrari G (2020) Lung ultrasound and the COVID-19 "Pattern": not all that glitters today is gold tomorrow. J Ultrasound Med 39(11):2281–2282. https://doi.org/10.1002/ium.15327
- 122. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA et al (2020) Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 18(8):1995–2002. https://doi.org/10.1111/ith.14888
- 123. Artifoni M, Danic G, Gautier G, Gicquel P, Boutoille D, Raffi F, Néel A, Lecomte R (2020) Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of Ddimer as predictive factors. J Thromb Thrombolysis 50(1):211–216. https:// doi.org/10.1007/s11239-020-02146-z
- 124. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J (2020) Chest CT for typical coronavirus disease 2019 (COVID-19) pneumonia: relationship to negative RT-PCR testing. Radiology. 296(2):E41–E45. https://doi.org/10.1148/radiol.202 0200343
- 125. Vetrugno L, Mojoli F, Boero E, Perchialla P, Bignami EG, Orso D, et al. (2021) Level of diffusion and training of lung ultrasound during the COVID-19 pandemic - A national online Italian survey (ITALUS) from the Lung Ultrasound Working Group of the Italian Society of Anesthesia, Analgesia, Resuscitation, and Intensive Care (SIAARTI). Ultraschall Med. English. https:// doi.org/10.1055/a-1634-4710. Epub ahead of print. PMID: 34734405.
- 126. Hussain A, Via G, Melniker L, Goffi A, Tavazzi G, Villen T et al (2020) Multiorgan point-of-care ultrasound for COVID-19 (PoCUSACOVID): international expert consensus. Crit Care 24(1):702. https://doi.org/10.1186/s13054-020-
- 127. Kiefl D, Eisenmann S, Michels G, Schmid M, Ludwing C, Pin M et al (2020) German recommendations on lung and thoracic ultrasonography in patients with COVID-19. Med Klin Intensivmed Notfmed 115(8):654–667. https://doi.org/10.1007/s00063-020-00740-w
- The British Medical Ultrasound Society. (2020) https://www.bmus.org/ policies-statements-guidelines/professional-guidance/covid-19-resources/. Archived 2021.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

